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ABSTRACT 
Reproductive senescence or menopause in women occurs when a female’s reproductive 
capability is terminated naturally by aging of the body or terminated abnormally because of 
factors such as exposure to environmental chemicals. For millions of women, the menopausal 
transition is accompanied by various debilitating symptoms including hot flashes and sleep 
disturbances. These symptoms may persist even years after they have started, leading to 
disrupted normal daily functioning. Previous studies have reported that race/ethnicity, body mass 
index, smoking status, and low estradiol levels may increase the risk of experiencing these 
debilitating menopausal symptoms. However, these risk factors do not fully explain why women 
have hot flashes and sleep disturbances and why these symptoms vary between and within 
women. Therefore, the first goal of my dissertation work was to better understand the role of the 
aryl hydrocarbon receptor (AHR) signaling pathway and the circadian locomotor output cycles 
kaput (CLOCK) gene in experiencing adverse reproductive outcomes during the transition into 
reproductive senescence. Specifically, I examined the associations between selected genetic 
polymorphisms in the AHR signaling pathway and menopausal hot flashes and I examined the 
associations between selected polymorphisms in the AHR signaling pathway, CLOCK, and sleep 
disturbances. To conduct this part of my doctoral work, I compared selected single nucleotide 
polymorphisms in the AHR signaling pathway and CLOCK, and sex steroid hormone levels in 
blood and serum samples from women (n=639) with and without hot flashes or sleep 
disturbances, enrolled in a midlife women’s health study. The results from my studies suggest 
that: 1) only CYP1B1 is associated with menopausal hot flashes via pathways that may involve 
changes in serum estradiol concentrations; and 2) AHRR and CLOCK may play roles in 
decreasing the risk of experiencing insomnia during the menopausal transition.  
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Previous studies indicate that environmental chemicals can accelerate timing to 
reproductive senescence by directly targeting ovarian follicles. Thus, in my dissertation work, I 
tested the hypothesis that various doses of bisphenol A (BPA) inhibit growth and reduce 
estradiol biosynthesis in isolated mouse antral follicles. I also tested the hypothesis that the toxic 
effects of BPA are mediated via the AHR signaling pathway. To test these hypotheses, I cultured 
mouse antral follicles with various doses of BPA (0.001-100 μg/ml) for up to 96 hours, while 
examining their growth every 24 hours. Expression levels of selected genes in the AHR signaling 
pathway and estradiol levels were measured at the end of the cultures. To further examine if the 
AHR is involved in mediating BPA toxic effects, I compared the ability of BPA to inhibit follicle 
growth and estradiol synthesis in follicles isolated from wild-type and Ahr global knock-out 
mice. Collectively, my data indicate that BPA at 25 μg/ml or higher inhibits follicle growth. 
Deletion of the Ahr only partially restores follicular growth following treatment with BPA 25 
μg/ml. Lastly, BPA exposure at doses equal or higher than 10 μg/ml decreases estradiol synthesis 
independent of the AHR signaling pathway. Overall, the findings from my doctoral work point 
toward a novel involvement of the AHR signaling pathway in various aspects of reproductive 
senescence and ovarian damage.  
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CHAPTER I 
Overview 
1.1 Overview 
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor 
that regulates physiological processes and mediates the effects of environmental 
toxicants, including those that are present in cigarette smoke. The AHR is evolutionarily 
conserved and crucial for normal fertility [1]. The activated AHR can induce expression 
of genes, including those that encode enzymes that can synthesize and degrade estradiol 
(E2). Moreover, the AHR can affect ovarian follicular development by acting through 
other pathways
 
involved in cell cycle regulation, proliferation and apoptosis [2-5]. 
Previous studies indicate that the AHR signaling pathway plays a role in female 
reproductive senescence [1, 6],
 
but the molecular mechanisms underlying its role in 
reproductive senescence are not fully understood.
 
Reproductive senescence (alternatively menopause in women) refers to the 
natural loss of female reproductive capability with age [1].
 
The transition into menopause 
is mainly characterized by depletion of the ovarian follicular reserve, accompanied by 
altered hormonal levels, predominantly a reduction in E2 levels [7]. During the 
menopausal transition, most women frequently experience various menopausal symptoms 
such as hot flashes [8, 9] and sleep disturbances [10]. 
Menopausal hot flashes are of concern because millions of women experience 
them as sudden, unpredicted, sensations of warmth and flushing of the skin.  These 
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symptoms can be accompanied by other debilitating symptoms such as sweating and 
mood changes. Thus, menopausal hot flashes can negatively affect the quality of life in 
women. Previous studies have shown that cigarette smoke, low E2 levels, race, and 
family history are associated with an increased risk of menopausal hot flashes. However, 
previous studies have not examined the role of genetic polymorphisms in the AHR 
signaling pathway as potential risk factors of menopausal hot flashes. Since the AHR can 
affect the estrogen biosynthesis pathway, it is possible that genetic alterations in the AHR 
signaling pathway may lead to lower estrogen levels and that this in turn may be 
associated with an increased risk of hot flashes. Additionally, the AHR can mediate the 
toxic effect of compounds present in cigarette smoke. Thus, genetic alterations in the 
AHR signaling pathway may lead to increased toxicity caused by cigarette smoke and 
this in turn may be associated with an increased risk of hot flashes.  
Menopausal hot flashes have also been suggested as a risk factor for sleep 
disturbances during the menopausal transition. However, not all generally healthy midlife 
women who experience hot flashes experience sleep disturbances [11, 12]. Even after hot 
flashes have diminished, some women continue to experience sleep disturbances [12, 13]. 
Normally, the main master regulators of circadian rhythms related to sleep/wake cycles 
are circadian locomotor output cycles kaput (CLOCK) and brain and muscle AHR 
nuclear translocator (ARNT)-like (BMAL1). These regulators along with a few members 
in the AHR signaling pathway belong to the basic helix-loop-helix (bHLH)/period-
ARNT-single minded (PAS) domain family. In addition, members of the AHR pathway 
have a daily oscillation rhythm of their own that operates in a tissue specific manner in 
rodents [14, 15]. Researchers have proposed a potential functional link between the AHR 
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signaling pathway and the circadian clock [16, 17].
 
Previous studies have examined 
alterations in circadian rhythms, such as those resulting from genetic variations [18-20]. 
However, selected genetic polymorphisms in the AHR signaling pathway and CLOCK 
have not been examined as potential risk factors for sleep disturbances during the 
menopausal transition. 
 As mentioned above, the AHR also mediates the toxic effects of environmental 
chemicals. Bisphenol A (BPA) is one of the most studied endocrine disrupting chemicals 
(EDCs) and is known to cause various toxic effects. For example, BPA treatment of 
cultured mouse ovarian follicles decreases steroidogenesis, leading to decreased E2 levels 
compared to the control group. However, its mechanism of action is unknown. Previous 
studies have mainly focused on whether BPA exerts its toxicity through nuclear receptors 
such as estrogen [21], androgen [22], and thyroid receptors [23, 24]. Since the AHR plays 
a crucial role in xenobiotic metabolism and interacts with the estrogen biosynthesis 
pathway [25], it is possible that it mediates some of the toxic effects of BPA as well. 
 The overall goal of my doctoral thesis work was to understand whether the AHR 
signaling pathway is involved in adverse reproductive outcomes or functions such as 
menopausal hot flashes, sleep disturbances, and inhibited follicular growth following 
exposure to BPA. Specifically, I tested the following three main hypotheses: (1) Selected 
single nucleotide polymorphisms (SNPs) in the AHR signaling pathway are associated 
with the risk of menopausal hot flashes via pathways that involve changes in serum E2 
concentration, (2) SNPs in the AHR signaling pathway and CLOCK are associated with 
the risk of menopausal sleep disturbances, and (3) BPA acts through the AHR signaling 
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pathway to increase E2 metabolism, leading to low E2 levels, followed by slow follicular 
growth. 
To test these hypotheses, I completed the following specific aims: 
Specific aim 1: To determine whether women carrying variant alleles of selected 
SNPs in the AHR signaling pathway have altered sex steroid hormones levels, 
leading to an increased risk of menopausal hot flashes. 
To complete this aim, I genotyped DNA samples donated by midlife women 
(n=639) who participated in a cross-sectional study on menopausal hot flashes. 
Specifically, I genotyped the samples for selected SNPs in the AHR signaling pathway 
(AHR rs2066853, AHRR rs2292596, ARNT rs2228099, CYP1B1 rs1800440). I then 
examined the associations between individual genotypes or combination of genotypes, 
sex steroid hormone levels, and hot flashes. Collectively, the data show that CYP1B1 is 
associated with menopausal hot flashes via pathways that may involve changes in serum 
E2 concentrations. The other SNPs in AHR, AHRR, and ARNT were not associated with 
the risk of hot flashes. These data are described in Chapter III.  
Specific aim 2: To determine whether midlife women carrying variant alleles of 
selected SNPs in the AHR signaling pathway and CLOCK have an increased risk of 
sleep disturbances compared to women not carrying the variant alleles. 
To complete this aim, I genotyped DNA samples donated by midlife women 
(n=639) who participated in a cross-sectional study on menopausal hot flashes. 
Specifically, I genotyped the samples for SNPs in the AHR signaling pathway (AHR 
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rs2066853, AHRR rs2292596, ARNT rs2228099) and CLOCK (rs1801260). I then 
examined the associations between individual genotypes or combination of genotypes, 
and selected sleep disturbances (i.e., insomnia and early awakening). Collectively, the 
data show that selected SNPs in the AHR signaling pathway (i.e., AHRR) and CLOCK 
may play a role in decreasing the risk of experiencing insomnia during the menopausal 
transition. None of the selected SNPs or combinations of SNPs were significantly 
associated with early awakening. These data are described in Chapter IV.  
Specific aim 3: To determine if BPA acts through the AHR signaling pathway to 
increase E2 metabolism, leading to low E2 levels, followed by slow antral follicular 
growth.  
To complete this aim, I cultured mouse antral follicles with vehicle control 
(dimethyl sulfoxide; DMSO) or BPA. Each culture lasted for 24 and 96 hours, and 
included a wide range of BPA treatments (0.001- 100 μg/ml). Then, I examined the 
effects of BPA treatments on follicular growth, E2 levels, and expression levels of 
selected genes in the AHR signaling pathway. I also cultured follicles from Ahr global 
knock-out mice (AhrKO) with vehicle or BPA (0.001- 100 μg/ml) and compared their 
growth and E2 biosynthesis. Collectively, the data show that BPA (50, 100 μg/ml) 
significantly inhibits wild-type follicle growth as early as 24 hours and BPA (25μg/ml) 
significantly inhibits wild-type follicle growth starting at 48 hours.  Additionally, BPA 
(10, 25, 50, 100 μg/ml) significantly decreases E2 levels in wild-type follicles compared 
to control. Interestingly, AhrKO follicles are partially rescued from the inhibition of 
growth exerted by BPA (25μg/ml). BPA treatment at the other doses resulted in a growth 
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pattern of AhrKO follicles similar to that of the wild-type follicles. Lastly, BPA (10, 25, 
50, 100 μg/ml) significantly decreases E2 levels in AhrKO follicles similar to that of the 
wild-type follicles.  These data are discussed in Chapter V. 
In summary, in chapter I, I have provided an overview of the entire dissertation. 
In chapter II, I have described the background of my studies. In chapter III, I have 
described the work related to the hypothesis that selected SNPs in the AHR signaling 
pathway are associated with an increased risk of menopausal hot flashes. In chapter IV, I 
have described the work related to the hypothesis that selected SNPs in the AHR 
signaling pathway and CLOCK are associated with an increased risk of sleep 
disturbances. In chapter V, I have described the work related to the hypothesis that BPA 
exposure has toxic effects on cultured mouse antral follicles, and the potential role of the 
AHR signaling pathway in mediating these toxic effects. In chapter VI, I have 
summarized my major findings, and suggested future research directions. Collectively, 
my dissertation work expands our knowledge of the link between the AHR and adverse 
reproductive outcomes.  
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CHAPTER II 
Background 
2.1 Background 
The AHR signaling pathway 
The AHR is a ligand activated transcription factor belonging to the basic helix-
loop-helix (bHLH)/Per/ARNT/Sim (PAS) family [1]. The AHR is present in almost all 
cell types and it is known to play a role in multiple cellular processes, including those 
involved in female reproduction [2-4]. Normally, unbound AHR is present in the 
cytoplasm, where it is associated with its chaperone proteins heat shock protein 90 
(Hsp90), immunophilin like protein XAP2, and co-chaperone p23 [2]. Upon ligand 
binding, the AHR translocates into the nucleus where it dissociates from its associated 
proteins. Then, the ligand bound receptor heterodimerizes with the aryl hydrocarbon 
nuclear translocator (ARNT). Further, the AHR-ARNT complex binds to specific 
enhancer sequences, also known as the xenobiotic response elements, with the consensus 
core recognition sequence of 5’-TNGCGTG-3’ [1, 5]. These sequences are localized 
adjacent to target promoters of various genes related to phase-I and phase-II xenobiotic 
metabolism [6, 7].
 
Upon binding of the AHR-ARNT complex to promoters, the 
transcription of phase-I and phase-II genes is initiated. AHR activity can be discontinued 
either by proteosomal degradation or upon binding of the ARNT to the AHR repressor 
(AHRR) [8-10].
  
The AHR is mostly known to bind environmental chemicals, including those 
present in cigarette smoke. The main biochemical groups known to bind the AHR are 
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halogenated aromatic hydrocarbons (including its most well known and most potent 
ligand 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin;TCDD), non-halogenated polycyclic 
aromatic hydrocarbons, and planar polychlorinated biphenyls. However, only a limited 
number of compounds have been proposed to be endogenous ligands for the AHR. These 
include tryptophan derivatives, arachidonic acid metabolites, and retinoids [1, 5, 11]. 
Further, in some instances it is possible that the AHR acts without an endogenous ligand 
because AHR-mediated actions that do not necessarily involve transcriptional changes 
have been documented in some studies [2, 12].  
 
The AHR signaling pathway is involved in multiple cellular processes including 
those in the mammalian ovary 
The mammalian ovary plays a central role throughout a female’s reproductive 
life, including the transition to reproductive senescence (i.e., menopause, in women). 
Within the ovary, the nonrenewable follicular pool serves as the main functional unit 
[13]. The follicles grow through several developmental stages, of which the antral follicle 
is the most mature form. This type of follicle is essential for reproduction because it is the 
only follicle type capable of ovulation. It is also the main source of sex steroid hormones, 
predominantly 17-β estradiol (E2), which is crucial both for proper fertility and 
maintenance of various tissues/organs in the body. Overall, from birth and throughout the 
reproductive lifespan, a balance between maturation and depletion of ovarian follicles 
must be maintained for normal fertility, reproductive function, and for timely onset of 
reproductive senescence.  
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The AHR is known to regulate multiple cellular processes including those in the 
reproductive system [4]. Some of the processes include cell-cycle regulation [14, 15], 
proliferation [15, 16], cell death [17, 18], and even circadian events [19, 20]. One of the 
most useful tools used to elucidate the role of the AHR in various processes is the global 
Ahr knock-out mouse (AhrKO) model. This mouse model was generated by several 
researchers [21-23], has been validated, and extensively studied in various contexts 
including reproductive ones [2-4, 24-26].
 
Interestingly, AhrKO females exhibit many 
reproductive disorders such as: 1) high abortion rate, 2) a reduction in the number of 
implantation sites, 3) difficulties in surviving pregnancy and lactation, 4) fewer litters, 5) 
smaller litters, 6) lower E2 levels, and 7) lower numbers of mature follicles compared to 
wild-type females [2-4, 26, 27].  
Though the time and sequence of events leading to reproductive senescence is 
different between mice and women, they do share similar indicators of reproductive 
senescence. These include reduced ovarian follicular reserve, irregular cycling, and 
steroid hormone fluctuations. In a recent paper, Valdez et al. [28]
 
reviewed studies that 
are suggestive of a link between activation of the AHR signaling pathway and accelerated 
transition to reproductive senescence both in animal models and women [28].
 
Other 
studies discuss the effects of known AHR ligands and their effects on reproductive 
senescence both in rodents and women. Specifically, cigarette smoking has been 
associated with diminished follicular reserve and early menopause in women similar to 
what was reported in rodents [29, 30]. Women accidently exposed to TCDD had an 
increased risk for earlier menopause compared to women who were not exposed to 
TCDD [31]. In lab animals, TCDD (1 μg/kg maternal body weight) exposure on 
13 
 
gestational day 8 in Long Evans Hooded rats resulted in accelerated onset of constant 
estrus and shortened reproductive lifespan compared to controls [32].
  
Similar results 
were reported by Franczak et al. [33]
 
in Sprague-Dawley rats exposed acutely or 
chronically with TCDD. Further, Chaffin et al. [34] reported that TCDD exposure on 
gestational day15 in Holtzman rats resulted in lower E2 levels on postnatal day 21 
compared to controls. Overall, the current literature is highly suggestive that activation of 
the AHR signaling pathway affects reproductive function and timing of reproductive 
senescence or menopause.  
It is possible that altered signaling of the AHR pathway will also result in 
differences in timing to reproductive senescence. Altered signaling in the AHR pathway 
can be a result of genetic polymorphisms. However, only a few studies have specifically 
examined the potential associations between selected SNPs in the AHR signaling 
pathway and female reproduction. Specifically, some studies have examined genetic 
polymorphisms in AHR gene (rs2066853; Arg>Lys), located at exon 10, in the trans-
activating domain of the receptor protein that is responsible for the initiation of 
transcription from the target genes that are related to reproductive functions in humans. 
These studies found that the SNP was not significantly associated with endometriosis 
[35-37]. Similarly, a synonymous polymorphism in ARNT (rs2228099;Val>Val) at exon 
7 was not predictive of endometriosis [35-37].
 
When a polymorphism at exon 5 of the 
AHRR gene (rs2292596; Pro>Ala) was evaluated in relation to endometriosis, conflicting 
results were reported. Tuschiya et al. [37]
 
found that the polymorphism was associated 
with both susceptibility and severity of endometriosis. The risk of endometriosis was 
approximately 2.5 times higher among Japanese women carrying any polymorphism in 
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the AHRR (Pro/Ala+Ala/Ala) compared to women who did not carry the polymorphism 
(Pro/Pro) [37]. The investigators suggested that these polymorphisms potentially 
facilitate proliferation of endometrial cells through diminished down-regulation of AHR-
mediated signaling [37]. However, these findings are not in agreement with those of 
Watanabe et al.[38] who found no association between the SNP and endometriosis or 
with those of Kim et al.[35] who found only a borderline association (p=0.06) between 
the polymorphism and endometriosis. Interestingly, Kim et al. [35]
 
reported a significant 
increase in the risk of endometriosis when the polymorphism in AHRR was combined 
with a polymorphism in the glutathione-S-transferase T1 (GSTT1) gene.  
 
The AHR signaling pathway and menopausal hot flashes 
Overall, findings from previously published papers point toward a solid role of 
the AHR signaling pathway in female reproduction. It is important to further study the 
role of the AHR in reproductive senescence by using animal models as well as data 
collected from human studies because high numbers of menopausal women experience 
debilitating symptoms during the transition to reproductive senescence, usually around 
the age of 52-54 years [39, 40].
 
Specifically, by the year of 2030, more than 1.2 billion 
women will be 50 years or older worldwide [41]. It is estimated that in the United States 
alone 6,000 women reach menopause daily [41]. By better understanding the reasons for 
adverse menopausal symptoms, we may be able to develop means to prevent or better 
treat them.  
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Menopause refers to the natural loss of female reproductive capability with age 
[28].
 
It is thought that menopause occurs because of depletion of the ovarian follicular 
reserve, accompanied by altered hormonal levels, predominantly a reduction in E2 levels 
[42]. Generally, natural menopause is determined retrospectively, while the menopausal 
transition is divided into several stages with particular characteristics. Burger et al. [43] 
summarized the widely accepted menopause nomenclature as follows: the late 
reproductive stage- characterized by no changes in menstrual cycle [follicle-stimulating 
hormone (FSH) levels may rise toward the end of this stage], the early menopausal 
transition stage- characterized by changes of ≥7 days in the menstrual cycle length, the 
late menopausal transition stage- characterized by ≥60 days of amenorrhea, and FSH 
levels of 40 IU/l or more which predict the final menstrual period, and the 
postmenopausal stage- ≥1 year of amenorrhea.  It is mainly during the menopausal 
transition stages when most women frequently experience various menopausal symptoms 
such as hot flashes [39] and sleep disturbances [44]. 
Menopausal hot flashes are usually defined as transient periods of intense 
sensations of heat mainly in the upper part of the body, arms and face.  There are three 
main clinical categories of hot flashes severity: mild (sensation of heat), moderate 
(sensation of heat accompanied by sweating), and severe (moderate symptoms with the 
disturbance of daily functioning) [39]. Hot flashes are often followed by flushing of the 
skin and profuse sweating [45] and may be followed by a sense of anxiety and 
palpitations. It is commonly thought that hot flashes occur as a result of disturbance of 
the temperature regulating mechanism located in the hypothalamus [46]. This disturbance 
is thought to lead to a reduction in the thermoneutral zone (within which fluctuations of 
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basal body temperature do not provoke compensatory vascular responses) so that even 
minor fluctuations in core body temperature reach the limits of the zone and initiate 
thermoregulatory response (Figure 2.1) [46].  
Unfortunately, millions of women worldwide experience menopausal hot flashes, 
which for many it may be severe and difficult to tolerate [45, 47].
 
Hot flashes can last 
from a few seconds to more than an hour and persist from one year in 95% of affected 
women up to 5 years in 65% of affected women [45, 47].
 
Additionally, the ways women 
experience hot flashes varies greatly among women and within women [48]. Despite the 
health burden that hot flashes impose on women’s lives, there is still a big gap in the 
knowledge of their precipitating events. As was described in our recent review paper 
[49],
 
investigators have identified several risk factors for hot flashes. Such risk factors 
include low estrogen levels,
 
cigarette smoking, genetics/family history, racial/ethnic 
background, body mass index, physical activity, mood status, alcohol consumption, 
dietary habits, other hormone levels (e.g., anti-Müllerian hormone, testosterone, and 
thyroid hormones), time to menopause, and menopausal stage.  
Although several risk factors for hot flashes have been identified, the etiology of 
hot flashes is still unknown. Due to the high variability in the way women experience hot 
flashes and the significant association between genetic background and hot flashes, I 
chose to expand our knowledge regarding genetics as potential risk factors of hot flashes. 
I focused on SNPs in the AHR signaling pathway that were identified to be related to 
other reproductive outcomes.  
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I decided to focus on the AHR signaling pathway for several reasons. First, the 
AHR can interact with the estrogen signaling and biosynthesis pathway, and its activity 
can affect the concentrations of sex steroid hormones [8, 9, 50, 51]. Given the known 
associations between 1) low serum estrogen concentrations and hot flashes [49, 52-54],
 
and 2) serum estrogen concentrations and genetic polymorphism in one of the 
downstream target genes in the AHR signaling pathway (i.e., CYP1B1) [55, 56], it is 
possible that women with hot flashes are more likely to carry genetic polymorphisms in 
the AHR signaling pathway genes than women without hot flashes.  
Second, another genetic polymorphism in the AHR signaling pathway (CYP1B1, 
rs1056836) was previously associated with hot flashes [57, 58]. Additionally, Hanna et 
al. [59]
 
reported a higher catalytic activity for one of the selected SNPs in CYP1B1 
(rs1800440), an enzyme that metabolizes E2 and thus, reduces levels of E2. Therefore, 
other genetic polymorphisms can be involved in experiencing hot flashes potentially by 
altering E2 levels.  
I specifically examined whether common SNPs reported in the AHR-rs2066853, 
AHRR-rs2292596, ARNT-rs2228099, CYP1B1-rs1800440, and CYP1B1-rs1056836, and 
combinations of these SNPs, are associated with the risk of hot flashes. Additionally, I 
examined if the selected SNPs were associated with altered sex steroid hormone 
concentrations or ratios and sex hormone binding globulin to determine if these 
differences could account for any observed association between the selected SNPs and 
hot flashes. The main findings from my study suggest that SNPs in the CYP1B1 gene 
(rs1800440, rs1056836) are associated with the risk of menopausal hot flashes, 
independent of known risk factors for hot flashes (e.g., E2 levels). 
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Menopausal sleep disturbances, CLOCK and the AHR signaling pathway 
As with hot flashes, women during the menopausal transition frequently 
experience sleep disturbances [60]. Sleep disturbances mainly include trouble falling 
asleep (also termed insomnia), waking in the middle of the night, and awakening early in 
the morning [61].
 
Women who experience sleep problems often suffer from daily/overall 
functioning impairment. Some of the suggested risk factors for sleep disturbances include 
hot flashes and night sweats [60, 62, 63], hormonal changes [63], time to menopause 
[64], menopausal status [60, 65],
 
and stress/mood state [63]. 
 
  
Normally, the main master regulators of circadian rhythms related to sleep/wake 
cycles are circadian locomotor output cycles kaput (CLOCK) and brain and muscle AHR 
nuclear translocator (ARNT)-like (BMAL1). Basically, the CLOCK/BMAL1 
heterodimer complex binds to the enhancer boxes of their target genes and further 
initiates the transcription/translation of inhibiting factors: periods (PER 1,2, and 3) and 
cryptochromes (CRY1 and 2). This leads to increased levels of the inhibiting complexes 
and results in reduced transcription/translation. This then allows consecutive action of 
CLOCK and BMAL1 [66]. Overall, the clock machinery acts in a feedback activation/ 
inhibition manner [67].
 
Previous studies have examined alterations in circadian rhythms resulting from 
genetic variations in the CLOCK gene [68, 69]. Mishima et al. [69] reported a significant 
association between the homozygosity of the CLOCK_C (rs1801260; T/C) allele and 
shorter sleep time. In contrast, Robilliard et al. [68] found no significant association 
between the selected CLOCK SNP and morning or evening preference. In a few studies, a 
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single nucleotide polymorphism (SNP) in CLOCK (rs1801260; T/C) has been associated 
with sleep differences such as evening preference and delayed timing of the sleep-wake 
cycle [69, 70]. Subjects carrying one or two copies of the CLOCK_C allele showed 
increased eveningness and reduced morningness, while subjects homozygous for 
CLOCK_T showed higher morningness scores [69, 70]. The CLOCK_CC genotype was 
also associated with delayed sleep timing and greater daytime sleepiness in Japanese 
[69],
 
but not in Caucasian women [68].  
Interestingly, the classical regulators of circadian rhythms along with a few 
members in the AHR signaling pathway belong to the basic helix-loop-helix 
(bHLH)/period-ARNT-single minded (PAS) domain family. The bHLH/PAS domains of 
BMAL1 and ARNT are extremely similar, and are thought to originate from the same 
ancestral gene [71]. In addition, members of the AHR pathway have a daily oscillation 
rhythm of their own that operates in a tissue specific manner in rodents [72, 73]. 
Furthermore, researchers have proposed a potential functional link between the AHR 
signaling pathway and the circadian clock [74, 75].  
However, selected genetic polymorphisms in the AHR signaling pathway and 
CLOCK have not been examined as potential risk factors for sleep disturbances during 
the menopausal transition. Therefore, as part of my doctoral work, I focused on whether 
selected SNPs are associated with sleep disturbances during the menopausal transition. 
Specifically, I examined if individual and combined SNPs in the CLOCK gene 
(rs1801260) and the AHR signaling pathway (AHR rs2066853, AHRR rs2292596, ARNT 
rs2228099) are associated with the risk of insomnia and early awakening among midlife 
women. The main findings from my study suggest a potential role of the AHR signaling 
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pathway in experiencing insomnia and early awakening during midlife. Further, my 
results suggest that the AHR signaling pathway may act alone or in combination with 
CLOCK. 
The first studies of my doctoral work focused on genetic polymorphisms in the 
AHR signaling pathway, CLOCK, and menopause related outcomes (i.e., hot flashes and 
sleep). Interestingly, under certain conditions, menopause can occur earlier than the 
median age of 48-52 [40]. Premature ovarian failure/menopause can affect 1% of all 
women under the age of 40 [76], whereas about 10-13% of women can undergo 
premature menopause between 40-47 years of age [40].
 
Accelerated time to menopause is 
a major concern because it is associated with an increased risk of various medical 
conditions such as osteoporosis [77], cardiovascular disease [78], and even earlier 
mortality [76, 79] compared to women who reach natural menopause at a normal age. 
One of the causes of premature menopause is ovarian toxicity [40]. Various 
environmental chemicals have been shown by epidemiological and experimental studies, 
to damage ovarian function, leading to early reproductive senescence [28, 40, 80].
 
These 
chemicals are termed endocrine disrupting chemicals (EDCs).   
 
Endocrine-disrupting chemicals and reproduction 
EDCs are natural or synthetic substances that are present in the environment and 
can alter the physiological hormonal and homeostatic systems [81]. This is primarily 
because EDCs can mimic, interfere with, or accelerate the action of physiological 
endocrine factors [81]. EDCs can exert their effects by acting through various mediators 
21 
 
such as nuclear receptors, membrane receptors, and enzymatic pathways [81]. Further, 
the effects of EDCs can involve multiple pathways simultaneously. For example, an EDC 
can affect the action of cell cycle regulators along with steroid synthesis.   
Interestingly, known ligands of the AHR such as compounds present in cigarette 
smoke or environmental chemicals (e.g. polyaromatic hydorcarbons, TCDD) have been 
linked with adverse reproductive outcomes that are characteristic of early reproductive 
senescence [28]. In the last part of my doctoral work, I specifically examined if another 
ubiquitous environmental chemical – BPA exerts ovarian toxicity via the AHR signaling 
pathway. 
 
The AHR signaling pathway and BPA 
BPA is a common name for 2,2-(4,4-dihydroxydiphenyl) propane that is 
synthesized by the combination of acetone and phenol (Figure 2.2) [82]. BPA was 
originally made in 1891 by Dianin [82]. In 1936, Dodds et al. reported that BPA has 
estrogenic properties and proposed to use it as a pharmaceutical agent [82, 83]. However, 
BPA was never used as a pharmaceutical agent [82, 83].
 
Instead, it became widely used 
in the plastic and epoxy resin industry in the 1950s [84], with an estimated worldwide 
yearly production volume of 11.5 billion pounds. Around the late 1990s, researchers 
reported that BPA can leach out of its products after heating, washing with detergents, or 
aging of plastics. Since then numerous studies have shown that BPA is ubiquitous in the 
environment [85, 86]
 
and it is present in human tissues and fluids [87-89]. For example, 
BPA is present in more than 93% of spot human urine samples [89]. Moreover, BPA has 
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been measured in ovarian follicular fluid in levels ranging between 1-2 ng/ml [90],
 
indicating that BPA can reach the ovary.  
In humans, BPA has a relatively short half-life (about 5-7 hours). Oral ingestion 
of the biologically active form of BPA (unconjugated BPA) is mainly cleared as 
glucuronide or sulfate conjugates in the urine [91]. However, studies suggest that BPA 
can be long-term stored in tissues (e.g., adipose tissue) and/or undergo conjugation-
deconjugation cycling [92]. According to one of the National Health and Nutrition 
Examination Survey (NHANES) studies, the adjusted mean BPA levels by age group 
were 4.5 ng/ml in children (6–11 years of age), 3.0 ng/ml in adolescents (12–19 years of 
age) and 2.5 ng/ml in adults (over 20 years of age). Moreover, maximum tolerated dose 
for BPA is considered to be 1,000 mg/kg/body weight/day
 
and
 
the calculated reference 
dose according to the US Environmental Protection Agency (EPA) was determined to be 
50 μg/kg/day based on the lowest observable adverse effect level (LOAEL) [83]. It is 
important to note that many studies report adverse outcomes even with BPA at lower 
levels than the reference dose [93].
 
I chose to focus on BPA in my studies for several reasons. First, BPA is one of 
the highest volume chemicals produced globally and it is likely that humans as well as 
wildlife species are constantly exposed to BPA [85, 87, 94].
 
Over 6 billion pounds of 
BPA are produced yearly by polycarbonate plastic and epoxy resin manufacturers. BPA 
is incorporated in various products such as food and drink packaging, flame retardants, 
building materials, baby bottles and toys, and even in dental sealants [85, 95, 96]. 
Furthermore, over 100 tons of BPA are released into the atmosphere due to natural 
degradation, industrial wastes, or following certain treatments such as exposure to heat 
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[82, 87, 93, 96, 97].
 
BPA has been detected in the soil, various water sources, and even in 
household dust [85, 98].
 
Notably, BPA levels have been estimated to reach up to 842 
μg/kg in canned foods and 0.03 to 4.5 μg/l (i.e., 0.14 to 19.7 nM) in canned soft drinks 
[99].  
Second, BPA has been identified as a top contaminant present in human tissues, 
and there is some evidence for its bioaccumulation in the human body [100-103].
 
Specifically, BPA has been detected in more than 93% urine samples of persons ≥ 6 years 
of age (0.4 to 49 μg/ml; 1.75 to 653 nM) [89]. Several studies indicate that human serum 
levels of BPA range from 1.4 to 19.3 nM, breast milk levels range from 1-7 ng/ml (i.e., 
4.4-30.6 nM), placental levels reach 104.9 ng/g placenta [87, 100, 103], and BPA levels 
are 36.4 nM in amniotic fluid [104]. Levels of BPA in follicular fluid range from 1-2 
ng/ml (i.e., 4.4-8.8 nM), indicating that BPA reaches the ovary [90].  
Third, BPA has significant effects on the endocrine and reproductive systems. In 
women, BPA has been associated with infertility [83], early menopause [87],
 
and other 
conditions such as polycystic ovarian syndrome [105].
 
In laboratory animals, BPA 
exposure alters sexual differentiation of reproductive tissues, advances puberty, causes 
abnormal sexually dimorphic behaviors, and causes weight gain [87, 101, 106-108]. 
Additionally, prenatal exposure of rodents to BPA causes formation of multiple cystic 
ovarian follicles, alters cyclicity, and impairs ovulation in adult life [106].
 
Interestingly, 
in vitro exposure to BPA of mouse ovarian cells results in impairment of meiotic 
maturation of the oocyte by altering both first and second meiotic divisions [109-112]. 
BPA (100 pM-100 µM) decreases viability of mouse granulosa cells (113).
 
Additionally, 
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BPA (100 μg/ml) inhibits the growth of mouse antral follicles and BPA at 10 or 100 
μg/ml decreases E2 synthesis compared to vehicle control treated follicles [114].  
Fourth, the effects of BPA have been shown to depend on timing and dose of 
exposure, tissue/cell type, and species. For example, in vitro treatment with BPA (1 µM) 
causes proliferation of MCF-7 cells [115], while BPA (100 pM-100 µM) decreases 
viability of mice granulosa cells [113]. Additionally, researchers suggest that BPA acts in 
a non-monotonic [82] 
 
dose response manner rather than a linear dose response.  Peretz et 
al. [114] found that BPA at 100 µg/ml inhibits the growth of cultured mouse antral 
follicles whereas BPA at 1 and 10 µg/ml had comparable growth to the vehicle control 
treated follicles. However, no studies have examined the effects of lower doses of BPA in 
a wide range of doses of BPA and their potential toxic effects on ovarian follicles. Thus, I 
specifically tested the hypothesis that a wide range of BPA doses causes U-shaped dose-
response effects on follicle growth and E2 levels. My findings suggest that BPA acts in a 
linear dose-response manner on the growth and E2 synthesis of cultured mouse ovarian 
follicles.  
 
The role of the AHR signaling pathway in mediating the toxic effects of BPA in 
mouse antral follicles 
Despite numerous studies that examined BPA toxicity, there is still no definitive 
mechanism of BPA action. Some studies have indicated that several signaling pathways 
are responsive to BPA exposure. Such pathways include estrogen [116], androgen [117], 
and thyroid [86, 118]
 
signaling pathways. However, Peretz et al. [119]
 
have shown that 
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BPA does not exert its toxic effects via the genomic estrogenic pathway in mouse ovarian 
follicles. Though the AHR mediates the toxic effects of several environmental chemicals, 
only a limited number of studies have examined the role of the AHR signaling pathway 
in mediating BPA toxic effects [120-122].
 
For example, Caserta et al. [120], reported a 
significantly higher percentage of samples positive for BPA (greater than level of 
detection) of infertile women compared to fertile women [120].
 
However, the researchers 
found no significant differences in the expression of the AHR between these two groups 
[120]. On the other hand,
 
BPA (5x10
-5 
M) acted as an antagonist for the AHR in cell 
based reporter assays [121]. Hence, part of my doctoral work was designed to expand our 
limited knowledge regarding the role of the AHR signaling pathway as a potential 
mediator of BPA toxic effects in ovarian follicles (please refer to my working model in 
Figure 2.3).  
The AHR signaling pathway was chosen for several reasons. First it mediates the 
effects of various environmental chemicals, including its most potent ligand 2,3,7,8,- 
tetrachlorodibenzo-p-dioxin (TCDD) [123]. Previous studies indicate that the BPA may 
bind to the AHR. For example, Nishizawa et al. [122] reported that following in utero 
exposure to BPA, Ahr expression was elevated in the gonads harvested from embryos, 
whereas Bonefeld-Jorgensen et al. [121] reported weak antagonistic effects of BPA with 
the AHR (AHR-CALUX system; mouse hepatoma cell line). 
Second, the AHR signaling pathway plays a central role in the ovary [4]. The 
AHR is involved in regulating the growth of pre-antral and antral follicles by increasing 
granulosa cell proliferation [124]. The AHR signaling pathway is also involved in 
regulation of E2 production by the ovary [51]. Specifically, activation of the AHR 
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signaling pathway can decrease the levels of E2 synthesizing enzymes (e.g., aromatase) 
and increase the levels of E2 metabolizing enzymes (e.g., CYP1B1) [125]. Karman et al. 
[126] found that exposure of cultured mouse antral follicles to various doses of the potent 
AHR ligand TCDD decreased E2 levels compared to control follicles. Peretz et al. [114] 
reported that antral follicles cultured with BPA (10, 100 μg/ml) also synthesized lower 
E2 levels compared to control follicles. Thus, my study examined the role of the AHR in 
mediating the toxic effects of BPA on antral follicles. I found that the AHR partially 
mediates the toxic effects of BPA on the growth of mouse antral follicles. Additionally, 
my studies indicate that the AHR probably does not play a role in mediating BPA toxic 
effects on E2 levels.  
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2.2 Figures and legends 
Figure 2.1: The thermonuetral zone of women who experience hot flashes versus 
asymptomatic women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Core body temperature (Tc) is regulated between an upper threshold for sweating and a 
lower threshold for shivering. In symptomatic women (women who experience hot 
flashes), it is thought that the thermoneutral zone is narrower allowing small Tc elevations 
to elicit hot flashes.  
(Adapted from Archer DF et al., 2011; [2]) 
Symptomatic 
(women experiencing hot flashes) 
Shivering threshold 
Sweating threshold 
Tc 
Reduce Tc 
Hot flashes 
Tc 
Thermoneutral zone 
Asymptomatic 
(women not experiencing hot flashes) 
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Figure 2.2: The chemical structure of 2,2-(4,4-dihydroxydiphenyl) propane also known 
as bisphenol A (BPA) 
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Figure 2.3: The potential role of the AHR in mediating BPA toxic effects – working 
model 
 
 
 
 
 
 
 
 
 
 
 
 
BPA exposure activates the AHR signaling pathway, leading to inhibited follicular 
growth, followed by decreased estradiol synthesis. 
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CHAPTER III 
Genetic polymorphisms in the aryl hydrocarbon receptor signaling pathway as 
potential risk factors of menopausal hot flashes
1
 
3.1 Abstract 
Objective:  We sought to determine if genetic polymorphisms in the aryl hydrocarbon 
receptor signaling pathway are associated with menopausal hot flashes via hormone 
levels. Study design: Women (n=639) aged 45-54 years completed a study survey and 
provided blood for genetic and hormone analyses. The associations were analyzed using 
multivariable logistic regression and generalized linear models. Results: Women carrying 
CYP1B1 (rs1800440) GG genotype had 3-fold greater odds of experiencing hot flashes 
for ≥1 year compared to the AA genotype (adjusted odds ratio [OR], 3.05; 95% 
confidence interval [CI], 1.12-8.25). Adding serum estradiol concentrations to the 
confounder-adjusted model resulted in a nonsignificant association (adjusted OR, 2.59; 
95% CI, 0.91-7.18). Carriers of both CYP1B1 (rs1800440) G and CYP1B1 (rs1058636) G 
alleles had higher odds of experiencing hot flashes for ≥1 year compared to women 
homozygous for the major alleles (adjusted OR, 1.77; 95% CI 1.06-2.96), even after 
adjustment for serum estradiol. Conclusion: CYP1B1 is associated with menopausal hot 
flashes via pathways that may involve changes in serum estradiol concentration.  
Key words: AHR (aryl hydrocarbon receptor), CYP1B1 (cytochrome P450 1B1), hot 
flashes, polymorphism, risk factor.  
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3.2 Introduction 
Menopausal hot flashes are one of the main reasons that millions of women seek 
medical care during their menopausal transition.
1,2
 It is estimated that about 5 million 
women in the United States alone will experience hot flashes each year.
2
 Most of these 
women will experience hot flashes for several months to 5 years, and some will even 
have hot flashes for up to 30 years.
2-4
 Nevertheless, little is known about the etiology of 
hot flashes
2-4
 although several risk factors have been identified. Such risk factors include 
African American race, high body mass index (BMI), cigarette smoking, and low serum 
estrogen concentrations.
3-8
 Additionally, a limited number of previous studies have 
shown that certain genetic polymorphisms in estrogen metabolizing enzymes (eg, 
cytochrome P450 1B1 [CYP1B1] rs1056836)
9,10
 and estrogen receptors
11,12 
are associated 
with an increased odds of hot flashes in midlife women. Thus, it is possible that 
additional genetic variations are associated with the risk of menopausal hot flashes.  
The aryl hydrocarbon receptor (AHR) is a highly conserved transcription factor 
that is present in many cell types. Upon ligand binding and activation of the receptor, 
the cytoplasmic AHR translocates to the nucleus and heterodimerizes with the AHR 
nuclear translocator (ARNT).
13 
This complex can then induce the transcription of 
specific genes that can further lead to estrogen biosynthesis (ie, aromatase) or 
degradation (ie, CYP1B1).
13-16 
The AHR repressor (AHRR) can block the activation of 
the AHR signaling pathway.
13
 
In the current study, we chose to focus on certain single nucleotide 
polymorphisms (SNPs) in the AHR signaling pathway as potential risk factors of 
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menopausal hot flashes for several reasons.  First, the AHR interacts with the estrogen 
biosynthesis pathway, and its activity can affect the concentrations of sex steroid 
hormones.
13-16
 Given the known associations between genetic polymorphisms (eg, 
CYP1B1) and serum estrogens concentrations,
9,17
 as well as between low serum 
estrogens concentrations and hot flashes,
3,4,18,19
 it is possible that women with hot 
flashes are more likely to carry genetic polymorphisms in the AHR signaling pathway 
genes than women without hot flashes. We specifically examined the potential 
associations between the AHR (rs2066853; missense), AHRR (rs2292596; missense), 
ARNT (rs2228099; synonymous), CYP1B1 (rs1800440; missense), and CYP1B1 
(rs1056836; missense) and selected hot flashes outcomes, although little is known 
regarding the functional significance of the selected polymorphisms. The exception is 
the CYP1B1 (rs1800440) polymorphism, for which Hanna et al.
20
 reported a higher 
catalytic activity for the variant allele compared to the non-variant allele in an in-vitro 
study. In a previous report, we found that a genetic polymorphism in the AHR 
signaling pathway (CYP1B1 rs1056836) was associated with hot flashes.
9,10
 Therefore, 
we hypothesized that common SNPs reported in the AHR, ARNT, AHRR, and CYP1B1 
genes, and combinations of these SNPs, are associated with the risk of hot flashes. In 
addition, we examined if the selected SNPs were associated with altered sex steroid 
hormone concentrations or ratios and sex hormone binding globulin (SHBG) to 
determine if these differences could account for any observed association between the 
selected SNPs and hot flashes.  
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3.3 Materials and Methods 
Participants (n=639) were recruited for a cross-sectional study of risk factors for 
menopausal hot flashes in midlife women. Detailed methods of participant recruitment 
are described elsewhere.
8
 Briefly, between 2000 and 2004, generally healthy women 
residing in Baltimore city and the surrounding counties were sent recruitment letters 
via mail. Potential participants had to meet the following eligibility criteria: aged 45 to 
54 years, not taking hormonal therapy, not pregnant, and no history of cancer.
8
 Further, 
because the study was designed to examine the health of women undergoing the 
menopausal transition, women were eligible only if they reported having at least three 
menstrual periods in the last 12 months. Therefore, all women in the study were either 
pre- or peri-menopausal. Eligible women were scheduled to come to the clinic during 
the morning hours and were instructed to fast overnight prior to the visit. During the 
clinic visit, each participant had their weight and height measured, and a blood sample 
was drawn for genetic and hormone concentrations analyses. The participants also 
completed the detailed study survey, which included questions regarding 
demographics; medical, family, and reproductive history; past exogenous hormone use, 
menopausal symptoms; and lifestyle habits (eg, smoking, diet). All participants in this 
study gave written informed consent according to procedures approved by the 
University of Illinois and Johns Hopkins University Institutional Review Boards. 
Age and race/ethnicity were self-reported. BMI was calculated based on height 
and weight measurements of the participant at the clinic visit and categorized either as 
normal BMI (≤24.9 kg/m2), overweight (25.0-29.9 kg/m2), or obese (≥30.0 kg/m2). 
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Smoking status at the time of enrollment (current/former/never) was determined using 
the questions “Have you ever smoked cigarettes?” and “Do you still smoke 
cigarettes?”  A woman’s history of ever experiencing midlife hot flashes was 
determined using the question “Have you ever experienced hot flashes?”  Women 
experiencing hot flashes were further queried regarding hot flash severity (mild, 
moderate, or severe), frequency (daily, weekly, or monthly), and duration (number of 
months/years). Hot flash outcomes examined in the analyses were: ever experienced 
hot flashes, moderate or severe hot flashes, daily hot flashes, and hot flashes 
experienced for one year or greater (long duration).  For all hot flash outcomes, the 
comparison group was never experienced hot flashes. 
SNPs genotyped to address the hypotheses were: AHR (rs2066853; Arg554Lys; 
G>A), AHRR (rs2292596; Pro185Ala; C>G), ARNT (rs2228099; Val89Val; G>C), and 
CYP1B1 (rs1800440; Asn453Ser; A>G). Additionally, genotype data for the SNP 
CYP1B1 (rs1056836; Leu432Val; C>G) that was reported in a previously published 
manuscript from this study were also used in the analyses.
9,10 
Genomic DNA was isolated from the donated blood samples using the 
GeneElute Blood Genomic DNA kit (Sigma-Aldrich, St. Louis, MO) and was 
amplified through polymerase chain reactions (PCR) based on published primers.
21,22
 
Genotyping of AHR, ARNT, and AHRR  SNPs was done using the allele-specific PCR 
method. Each reaction tube of AHR, ARNT, and AHRR contained: DNA sample 3µL, 
HotStarTaq Plus Master mix (Qiagen, USA) 10µL, 10X reaction buffer 2µL 
(QIAGEN, USA), forward and reverse primers (50mM) 0.1µL of each, allele-specific 
primer (50mM) 0.1µL (AHR) 0.02µL (AHRR, ARNT), and RNase free water 4.7µL 
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(AHR) 4.78µL (ARNT, AHRR). Each CYP1B1 PCR reaction tube contained: DNA 
sample 3µL, HotStarTaq Plus DNA polymerase 0.1µL (5U/µl; Qiagen), 10X reaction 
buffer 2µL (Qiagen), forward and reverse primers (50mM) 0.1µL of each, RNase free 
water 14.3µL (Qiagen), and dNTPs (10mM; Invitrogen, Carlsbad, CA) 0.4µL. PCR 
protocols included: activation at 95°C for 5 minutes, denaturation at 94°C for 45 sec, 
annealing at 63°C [AHR, AHRR], 57°C (ARNT), or 60°C (CYP1B1) for 45 seconds, 
elongation at 72°C for 45 seconds (denaturation to elongation steps were repeated 30 
cycles [AHR, CYP1B1] or 33 cycles [AHRR, ARNT]), final elongation at 72°C for 5 
minutes, and lastly 10°C for 5 minutes. CYP1B1 PCR products were digested with 
restriction enzyme (MwoI; New England BioLabs, Inc., Ipswich, MA). All products 
were visualized by 2.5% (AHR, ARNT, AHRR) or 3.0% (CYP1B1) agarose gel 
electrophoresis. Participants were categorized according to the genotype for each SNP 
as homozygous for the major allele, heterozygous, or homozygous for the minor allele. 
Serum concentrations of estradiol, estrone, testosterone, progesterone and 
SHBG were measured using enzyme-linked immunosorbent assays. All assays were 
performed as previously described.
8
 Briefly, the assays were run using the 
manufacturers’ instructions. All assays were conducted in the same laboratory by a 
single investigator. All samples were run in duplicate and mean values for each 
participant were used in the analyses. The laboratory personnel were blind with respect 
to any information concerning study subjects. In addition, positive controls containing 
known amounts of the tested hormone or SHBG were included in each batch. Further, 
some samples were run in multiple assays to ensure that the assay values did not 
dramatically shift over time.
8
 The minimum detection limits for the estradiol, estrone, 
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testosterone, androstenedione, progesterone, and SHBG assays were 7 pg/mL, 10 
pg/mL, 0.04 ng/mL, 0.03 ng/ml, 0.1 ng/mL, and 0.1 nmol/L, respectively. No estradiol, 
estrone, testosterone, androstenedione, or SHBG measurements were below the limit of 
detection. For progesterone measurements that were below the limit of detection (n = 
66), the value was set at the limit of detection (0.1 ng/mL). The average intra-assay 
coefficient of variation was 3.3±0.17% for estradiol, 4.8±0.25% for estrone, 2.2±
0.56% for testosterone, 2.5±0.60% for androstenedione, 2.1±0.65% for progesterone, 
and 2.4±0.67% for SHBG. The average inter-assay co-efficient of variation for all 
assays was less than 5%.
7
 To assess the amount of unbound serum estradiol or 
testosterone, ratios of serum estradiol to SHBG and serum testosterone to SHBG were 
calculated as described previously to generate free serum estradiol indices and free 
serum testosterone indices.
8 
 
The associations between the SNPs and both the categorical covariates and hot 
flash outcome variables were analyzed using chi-square tests. Both unadjusted and 
confounder-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for 
associations between the SNPs and the hot flash outcome variables were generated 
using logistic regression models. The following covariates were included as potential 
confounders in all of the logistic regression models, as they were associated with ever 
experiencing hot flashes in previous analyses from this study or in the published 
literature: race, BMI, smoking status, age. In addition, race-stratified analyses were 
conducted to examine differences in the analyzed associations between Caucasian and 
African American women in the sample; however, the OR estimates did not 
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substantially differ and, therefore, we determined that race was not an effect modifier. 
Thus, instead of presenting the race-stratified results, we treated race as a confounder 
in the analyses along with BMI, age and smoking status. Lastly, generalized linear 
models were used to examine the associations between the SNPs and hormone 
concentrations, ratios, and SHBG. Analyses were performed using SAS software 
(version 9.1; SAS Institute Inc., Cary, NC). A P value < 0.05 was considered to be 
statistically significant. 
3.4 Results 
Characteristics and genotype distributions of the study sample by hot flash 
status are presented in Table 1. Women with hot flashes were significantly older and 
more likely to be African American, to be overweight or obese, and to smoke 
cigarettes compared to women without hot flashes. The percentages of women with 
genetic polymorphisms were not significantly different between women with and 
without hot flashes. We used the Hardy-Weinberg equation to estimate if the observed 
genotype frequencies in our study sample differed from the predicted genetic variation 
at equilibrium of the general population. All SNPs excluding AHR and AHRR were in 
Hardy-Weinberg equilibrium (data not shown), indicating that there was a stable 
frequency distribution of these genotypes in our study compared to the predicted 
variation of the general population. In the unadjusted analyses, the AHR SNP was 
associated with ever experiencing hot flashes (Table 2). Specifically, women 
homozygous for the AHR minor allele (rs2066853 A) had increased odds of any hot 
flashes (OR, 2.67; 95% CI, 1.13-6.33) compared to women homozygous for the major 
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allele (rs2066853 G). However, after adjustment for age, race, BMI, and smoking 
status, this association was attenuated and no longer statistically significant (OR, 2.44; 
95% CI, 0.99-6.01). Similarly, the combined genotypes of the AHR and CYP1B1 
(rs1800440) SNPs were significantly associated with ever experiencing hot flashes 
only in the unadjusted statistical model (OR, 1.93; 95% CI, 1.00-3.75). The combined 
genotypes of the CYP1B1 SNPs (rs1800440 and rs1056836) were also associated with 
ever experiencing hot flashes, but only in the confounder adjusted model (OR, 1.51; 
95% CI, 1.01-2.31). None of the other SNPs or combinations of SNPs were 
significantly associated with ever experiencing hot flashes in the unadjusted or 
adjusted analyses.  
The results of the analyses examining the selected SNP genotypes and the 
severity, frequency, and duration of hot flashes are shown in Table 3.  Hot flash 
severity was significantly associated only with the combined genotypes of the selected 
SNPs in CYP1B1. Specifically, carriers of at least one minor allele for both CYP1B1 
SNPs (rs1800440 G and rs1056836 G) had greater odds of moderate or severe hot 
flashes compared to women who were homozygous for the major allele of both 
CYP1B1 SNPs (OR, 1.68; 95% CI, 1.00-2.82). Long lasting hot flashes (hot flashes 
experienced for a year or more) were more likely to be experienced among women 
homozygous for minor allele of the AHR (rs2066853 A), CYP1B1 (rs1800440 G), or 
combined SNPs of the CYP1B1 (rs1800440 G and rs1056836 G) compared to women 
who were homozygous for the major alleles; however, only the associations between 
the CYP1B1 SNP (rs1800440) and combined CYP1B1 SNPs (rs1800440 and 
rs1056836) remained statistically significant after adjustment for the other covariates.  
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Hot flash frequency was not significantly associated with any of the SNPs or their 
combinations. 
The associations between the selected SNPs and hormones as well as SHBG 
are shown in Table 4. Women homozygous for the major allele of AHR (rs2066853 G), 
ARNT (rs2228099 G), and CYP1B1 (rs1800440 A) had significantly higher serum 
concentrations of SHBG, estrone and estradiol, respectively, compared to carriers of 
the minor alleles (homozygous or heterozygous) of those genes. Additionally, 
significant associations were observed for the combined genotypes of AHR 
(rs2066853) and AHRR (rs2292596) and SHBG and free testosterone index and 
between AHR (rs2066853) and ARNT (rs2228099) and serum estradiol, estrone, and 
testosterone concentration (Table 5). No other statistically significant associations were 
observed between the individual SNPs or their combinations and hormone 
concentrations, ratios or SHBG.  
Lastly, to examine whether the statistically significant associations observed 
between the SNPs and hot flashes outcome variables in the adjusted analyses were due 
to observed differences in hormone concentrations, the hormone variable was added to 
the multivariable logistic regression model for the specific SNP and hot flashes 
outcome where a statistically significant association was found.  Adding the serum 
estradiol concentration variable to the statistical model resulted in attenuation of the 
association between CYP1B1 (rs1800440) and hot flashes experienced for more than a 
year (OR, 2.59; 95% CI, 0.91-7.18).  No further analyses were conducted for the 
combined CYP1B1 SNPs and either of the other hot flash outcomes as the combined 
52 
 
CYP1B1 genotypes were not significantly associated with any of the hormone 
concentrations.  
3.5 Comment  
Findings from this study suggest that SNPs in the CYP1B1 gene (rs1800440, 
rs1056836) are associated with the risk of menopausal hot flashes, independent of 
known risk factors for hot flashes. Furthermore, our results indicate that genetic 
polymorphisms in the AHR signaling pathway (ie, AHR, ARNT, CYP1B1 and the 
combined genotypes AHR and ARNT; AHR and AHRR) are correlated with sex steroid 
hormone concentrations, SHBG concentration, and hormone ratios. 
In our current study, women homozygous for the minor allele of the AHR SNP 
(rs2066853 A) had almost a three-fold greater odds of any hot flashes and hot flashes 
experienced for more than a year in our unadjusted models compared to women 
homozygous for the major allele (rs2066853 G). These associations, however, were 
attenuated when the statistical model was adjusted for BMI, race, age, and smoking 
status. This finding suggests that the AHR SNP is not an independent risk factor for hot 
flashes and that BMI, race, age, and smoking status confound the observed associations 
with hot flashes. These findings are in accordance with studies conducted in our sample 
and others indicating that high BMI, African American race, and cigarette smoking are 
strongly associated with increased odds of hot flashes
5-8,23-25
 In our study sample, women 
who were homozygous for the major AHR allele (rs2066853 G) included a significantly 
higher percentage of African American women (22.3% versus 16.0%), and women with 
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higher BMI (BMI>30.0 kg/m
2
; 60% versus 7.9%) compared to women homozygous for 
the minor allele.  
In this study, we also found that CYP1B1 (rs1800440) was significantly 
associated with long lasting hot flashes in the confounder adjusted statistical model 
that included BMI, race, age, and smoking status. This association was attenuated 
when serum estradiol was added to the model, suggesting that serum estradiol 
concentration may mediate the association between CYP1B1 (rs1800440) and long 
lasting hot flashes. Though there is limited information regarding the direct effects of 
this SNP on CYP1B1 activity,
26
 its potential effects in the context of various 
haplotypes, or its association with hot flashes,
27
 it is possible that the SNP leads to an 
increase in CYP1B1 enzyme activity. This, in turn, may reduce serum estradiol 
concentration and thus increase the risk of hot flashes. Hanna et al.
20
 reported a higher 
catalytic activity for the CYP1B1 (rs1800440) variant than the non-variant form in an 
in-vitro study. Specifically, in our study, increased enzyme activity is possible in the 
light of the significant association between the SNP and lower serum estradiol 
concentration.  
The association between CYP1B1 (rs1800440) and hot flashes is intriguing 
because the observed OR in the confounder adjusted model was relatively high (OR, 
3.05) compared to other published risk factors for hot flashes, such as cigarette 
smoking and race (OR, 1.55,
7
 risk ratio: 2.08
23
 respectively). Moreover, it is the second 
SNP in the CYP1B1
9,10
 that has been reported to be significantly associated with hot 
flashes. In one of our previous studies, women heterozygous or homozygous for the 
CYP1B1 minor allele (rs1056836 C) had a 27% higher risk (risk ratio, 1.27; 95% CI, 
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1.00-1.61) of long lasting hot flashes compared to women who were homozygous for 
the major allele (rs1056836 C).
9 
In our combined analysis of the two SNPs in CYP1B1 
(rs1800440 and rs1056836), the increased odds of long lasting hot flashes was still 
observed, but with a lower OR than of CYP1B1 (rs1800440) alone. Another finding 
that suggests a potential role for these SNPs in the way women experience hot flashes 
is that the combined CYP1B1 genotypes were also associated with hot flash severity. 
Generally, we can only speculate that due to a relative proximity of the SNPs in the 
CYP1B1 gene (codons 432 and 453), there may be some cross effects that attenuate the 
odds of long lasting hot flashes or that other factors that were not assessed in our 
current study attenuated the odds of long lasting hot flashes when we analyzed the 
combination of the two SNPs. 
We also observed that the AHRR (rs229296) and ARNT (rs2228099) SNPs were 
not significantly associated with any of the hot flash outcomes. The data suggest that 
these SNPs do not play a central role in the etiology of hot flashes despite their major 
role in the AHR signaling pathway.  
Overall, this study had several strengths as well as limitations. Some of the 
strengths are the relatively large sample size and the novel focus on selected individual 
SNPs and their combinations in the AHR signaling pathway. Additionally, this study 
included generally healthy women during their menopausal transition, a time in which 
hot flashes are likely to be experienced. Since hot flashes can be experienced 
differently between individuals, the study participants were asked specific questions 
regarding different aspects of hot flashes (ie, any hot flashes, severity, duration, 
frequency). Nevertheless, the presented results must be considered in the context of the 
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study limitations. Although we focused on selected SNPs that are common in the 
population, we only examined a limited number of them, and in a defined set of study 
participants. Potentially, there may be other SNPs that affect the risk of hot flashes 
solely or when combined with other SNPs.
28
 Moreover, the numbers of women who 
were homozygous for the minor allele of AHR, AHRR and CYP1B1 were relatively 
small. Thus, we might have a type 2 error/lack of statistical power to detect possible 
effects of some of the minor alleles. It is also possible that our study design (cross-
sectional) did not allow us to identify more statistically significant associations due to 
the high variability in the way and/or the timing women experience hot flashes.  
In conclusion, our results suggest that some genes in the AHR signaling pathway 
may play a role in the etiology of hot flashes. Further studies should investigate the 
potential roles of individual SNPs, combinations of SNPs, and hormone concentrations to 
obtain a better understanding of their potential role as risk factors for menopausal hot 
flashes.  
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3.6 Tables 
Table 3.1: Sample characteristics (Baltimore metropolitan area, 2000-2004) 
Variable Women 
without hot 
flashes 
Women with 
hot flashes 
p value 
n     (%)
a 
n     (%)
a 
Total sample size  267 372  
Age group (years)    
45 to 49 194 (72.7) 219 (58.9) <0.01 
50 to 54 73 (27.3) 153 (41.1)  
Race    
Caucasian 230 (86.1) 302 (81.2) 0.01 
African American 28 (10.5) 66 (17.7)  
Other 8   (2.9) 3   (0.8)  
Body mass index (kg/m
2
)   <0.01 
<25.0 127 (47.6) 146 (39.2)  
25.0 to 29.9 81 (30.3) 94 (25.3)  
>30.0 59 (22.1) 131 (35.2)  
Cigarette smoking   0.01 
Current  16  (6.0) 42 (11.3)  
Former   94(35.2) 153 (41.1)  
Never      157 (58.8)           176 (47.3)    
AHR (rs2066853)   0.06 
+/+ (GG) 190 (71.4) 244 (65.8)  
+/-  (GA) 69 (25.9) 103 (27.7)  
 -/-  (AA) 7   (2.7)       24   (6.5)  
AHRR (rs2292596)   0.99 
+/+ (CC) 111 (41.7) 157 (42.3)  
+/-  (CG) 144 (54.1) 199 (53.6)  
-/-   (GG)  11   (4.2)       15   (4.1)  
ARNT (rs2228099)   0.82 
+/+ (GG) 84 (31.6) 126 (34.0)  
+/-  (GC) 136 (51.1) 182 (49.0)  
-/-   (CC) 46 (17.3) 63 (17.0)  
CYP1B1 (rs1800440)   0.19 
+/+ (AA) 186 (69.9) 251 (67.5)  
+/-  (AG) 74 (27.8) 102 (27.4)  
-/-   (GG) 6   (2.3)     19   (5.1)  
CYP1B1 (rs1056836)   0.30 
+/+ (CC) 77 (28.9)  87 (23.5)  
+/-  (CG) 122 (45.9) 180 (48.7)  
-/-   (GG) 67 (25.2) 103 (27.8)  
a
Due to missing information, some columns do not add up to the total n listed, and 
percentages do not add up to 100 
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Table 3.2: The associations between the selected SNPs and ever experiencing hot 
flashes  
Genotype Women 
without 
hot flashes 
Women 
with hot 
flashes 
Unadjusted 
Model 
b
Adjusted model 
 n
a 
n
a 
OR 95% CI
 
OR 95% CI
 
AHR (rs2066853)
       
+/+ (GG) 190 244 1.00 Referent 1.00 Referent 
+/-  (GA)  69 103 1.16 0.81,1.67 1.08  0.72, 1.60 
 -/-  (AA)   7  24 2.67 1.13, 6.33 2.44  0.99, 6.01 
AHRR (rs2292596)       
+/+ (CC) 111 157 1.00 Referent 1.00 Referent 
+/-  (CG) 144 199 0.98  0.71, 1.35 1.03  0.73, 1.46 
-/-   (GG)   11  15 0.96  0.43, 2.18 0.84  0.36, 1.98 
ARNT (rs2228099)       
+/+ (GG)   84 126 1.00 Referent 1.00 Referent 
+/-  (GC) 136 182 0.89  0.63, 1.27 0.86  0.59, 1.24 
-/-   (CC)  46  63 0.91  0.57, 1.46 0.83  0.51 1.35 
CYP1B1 (rs1800440)       
+/+ (AA) 186 251 1.00 Referent 1.00 Referent 
+/-  (AG)  74 102 1.02  0.72, 1.46 1.07  0.74, 1.55 
-/-   (GG)   6  19 2.35  0.92, 5.99 2.49  0.95, 6.48 
AHR and AHRR       
+/+ and +/+ 78 90 1.00 Referent 1.00 Referent 
+/+ and +/- or -/-      145      221 1.32  0.91, 1.91 1.29  0.88, 1.88 
+/-,-/- and +/-, -/- 43 60 1.21 0.74, 1.98 1.12  0.67, 1.86 
AHR and ARNT        
+/+ and +/+  63 85 1.00 Referent 1.00 Referent 
+/+ and +/- or -/-       148     200 1.00 0.68, 1.48 0.92  0.61, 1.38 
+/-,-/- and +/-, -/-  55 86 1.16 0.73, 1.85 0.99  0.60, 1.65 
AHR and CYP1B1       
+/+ and +/+ 123 159 1.00 Referent 1.00 Referent 
+/+ and +/- or -/- 128 177 1.07 0.77, 1.48 1.00  0.72, 1.41 
+/-,-/- and +/-, -/-  14  35 1.93 1.00, 3.75 1.87  0.95, 3.70 
CYP1B1 and CYP1B1 (rs1056836)      
+/+ and +/+   75  84 1.00 Referent 1.00 Referent 
+/+ and +/- or -/-        112     169 1.35  0.91, 2.00 1.51  1.01, 2.31 
+/-,-/- and +/-, -/-   78     117 1.34  0.88, 2.05 1.54 0.97, 2.42 
Reference group for each examined SNP was women homozygous for the major allele 
  SNP= single nucleotide polymorphism
  
   a
Due to missing information, some columns do not add up to the total n listed, and   
  percentages do not add up to 100 
   b
Confounder adjusted model; Adjusted for race, body mass index, age, and smoking status  
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Table 3.3: The associations between the selected SNPs and type of hot flashes
a
  
Genotype n 
 
Moderate or severe hot flashes n 
 
Hot flashes for ≥1 year n 
 
Daily hot flashes 
Unadjusted model bAdjusted model Unadjusted model bAdjusted model Unadjusted model 
bAdjusted model 
  OR 95% CI
 OR 95% CI  OR 95% CI OR 95% CI  OR 95% CI OR 95% CI 
AHR (rs2066853)              
+/+ (GG) 152 1.00 Referent 1.00 Referent 159 1.00 Referent 1.00 Referent 52 1.00 Referent 1.00 Referent 
+/-  (GA)  69 1.25  0.84, 1.86 1.14  0.73, 1.76  65 1.13  0.76, 1.68 0.95  0.61, 1.49 28 1.48  0.87, 2.53 1.46 0.81, 2.64 
 -/-  (AA)  14 2.50  0.98, 6.35 2.21  0.82, 5.96  17 2.90  1.17, 7.17 2.37  0.90, 6.21   5 2.61 0.80, 8.56 2.66  0.70, 10.11 
AHRR (rs2292596)               
+/+ (CC)  90 1.00 Referent 1.00 Referent 105 1.00 Referent 1.00 Referent 35 1.00 Referent 1.00 Referent 
+/-  (CG) 132  1.13  0.79, 1.63 1.22  0.83, 1.79 128 0.94  0.66, 1.34 0.97  0.66, 1.42 48 1.06 0.64, 1.75 1.12  0.66, 1.90 
-/-   (GG)  13 1.46  0.62, 3.41 1.30  0.53, 3.18     8 0.77 0.30, 1.99 0.60 0.22, 1.66   2 0.58 0.12, 2.73 0.59 0.12, 3.02 
ARNT (rs2228099)               
+/+ (GG)  84 1.00 Referent 1.00 Referent   83 1.00 Referent 1.00 Referent 28 1.00 Referent 1.00 Referent 
+/-  (GC) 109 0.80  0.54, 1.19 0.77 0.51, 1.16 118 0.88  0.59, 1.30 0.87  0.58, 1.31 42 0.93 0.53, 1.61 0.82  0.45, 1.47 
-/-   (CC)  42 0.91  0.55, 1.53 0.81  0.47, 1.39   40 0.88 0.52, 1.48 0.83  0.48, 1.43 15 0.98 0.48, 2.02 0.79  0.36, 1.70 
CYP1B1 (rs1800440)               
+/+ (AA) 159 1.00 Referent 1.00 Referent 163 1.00 Referent 1.00 Referent 59 1.00 Referent 1.00 Referent 
+/-  (AG)   64 1.01  0.68, 1.50 1.04  0.68, 1.58  64 0.99 0.67, 1.47 1.10  0.72, 1.67 24 1.02 0.59, 1.76 1.14  0.63, 2.05 
-/-   (GG)   13 2.53  0.94, 6.82 2.62  0.94, 7.31  15 2.85  1.08, 7.52 3.05  1.12, 8.25   3 1.58 0.38, 6.50 1.60 0.36, 7.20 
AHR and AHRR                
+/+ and +/+ 53 1.00 Referent 1.00 Referent 65 1.00 Referent 1.00 Referent 21 1.00 Referent 1.00 Referent 
+/+ and +/- or -/- 136 1.38  0.91, 2.10 1.38 0.89, 2.13 134 1.11  0.74, 1.66 0.98  0.64, 1.49 45 1.15 0.64, 2.07 1.24  0.66, 2.31 
+/-,-/- and +/-, -/- 46 1.57  0.92, 2.71 1.44  0.81, 2.55 42 1.17 0.69, 2.01 0.99  0.55, 1.74 19 1.64 0.80, 3.38 1.61  0.74, 3.50 
AHR and ARNT                
+/+ and +/+ 58 1.00 Referent 1.00 Referent 55 1.00 Referent 1.00 Referent 16 1.00 Referent 1.00 Referent 
+/+ and +/- or -/- 120 0.88  0.57, 1.35 0.79  0.51, 1.24 132 1.02  0.66, 1.57 0.93  0.59, 1.46 48 1.28 0.68, 1.52 1.11 0.56, 2.20 
+/-,-/- and +/-, -/- 57 1.13  0.67, 1.88 0.94  0.53, 1.64 54 1.13  0.67, 1.89 0.90  0.51, 1.60 21 1.50 0.71, 3.16 1.24 0.54, 2.83 
AHR and CYP1B1             
+/+ and +/+ 98 1.00 Referent 1.00 Referent 102 1.00 Referent 1.00 Referent 33 1.00 Referent 1.00 Referent 
+/+ and +/- or -/- 115 1.13  0.78, 1.63 1.06  0.72, 1.55 118 1.11  0.77, 1.60 1.01  0.69, 1.48 45 1.31 0.79, 2.19 1.28  0.74, 2.22 
+/-,-/- and +/-, -/- 22 1.97  0.96, 4.06 1.72  0.82, 3.64   21 1.81  0.88, 3.74 1.71  0.81, 3.62  7 1.86 0.70, 4.99 2.11  0.75, 5.95 
CYP1B1 and CYP1B1(rs1056836)           
+/+ and +/+ 48 1.00 Referent 1.00 Referent 53 1.00 Referent 1.00 Referent 18 1.00 Referent 1.00 Referent 
+/+ and +/- or -/-   113 1.58  1.01, 2.46 1.81  1.13, 2.89 110 1.39  0.90, 2.16 1.64  1.02, 2.62 41 1.53 0.82, 2.85 1.84  0.93, 3.65 
+/-,-/- and +/-, -/- 74 1.48  0.92, 2.40 1.68  1.00, 2.82 79 1.43 0.90, 2.30 1.77 1.06, 2.96 26 1.39 0.70, 2.74 1.74 0.82, 3.69 
Reference group for each examined SNP was women homozygous for the major allele; SNP= single nucleotide polymorphism  
a The comparison group for all hot flash outcomes was women who reported that they never experienced hot flashes 
b Confounder adjusted model; Adjusted for race, body mass index, age, and smoking status  
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    Table 3.4: The association between SNPs and hormone serum concentrations, ratios, and SHBG concentration 
Genotype Estradiol (pg/mL) 
 
 
Estrone (pg/mL) 
 
 
Testosterone 
(ng/mL) 
 
Progesterone 
(ng/mL) 
 
SHBG (nmol/L) 
 
 
Free estradiol index 
 
 
Free testosterone 
index 
 
Geometric 
mean 
95% LL, UL 
p 
value 
Geometric 
mean 
95%LL, UL 
p 
value 
Geometric 
mean 
 95%LL, UL 
p 
value 
Geometric 
mean 
 95%LL, UL 
p 
value 
Geometric 
mean 
 95%LL, UL 
p 
value 
Geometric 
mean 
 95%LL, UL 
p 
value 
Geometric 
mean 
95%LL, UL 
p 
value 
AHR (rs2066853)              
+/+ (GG) 101.28 
93.79, 109.37 
0.21 136.10 
127.27, 145.54 
0.06 0.46 
0.43, 0.49 
0.41 0.83 
0.73, 0.95 
0.38 59.62 
56.34, 63.08 
0.05 0.62 
0.57, 0.68 
0.77 2.66 
2.44, 2.90 
0.07 
+/-  (GA) 89.83 
79.50, 101.49 
 129.25 
116.19, 143.78 
 0.49 
0.44, 0.53 
 0.76 
0.61, 0.94 
 54.66 
49.97, 59.79 
 0.60 
0.52, 0.70 
 3.09 
2.69, 3.55 
 
 -/-  (AA) 88.63 
66.48, 118.16 
 100.32 
78.06, 128.94 
 0.49 
0.29, 0.61 
 0.59 
0.35, 0.98 
 47.22 
38.22, 58.34 
 0.69 
0.49, 0.97 
 3.59 
2.59, 4.97 
 
AHRR (rs2292596)              
+/+ (CC) 95.41 
86.50, 105.23 
0.83 133.02 
122.10, 144.92 
0.80 0.45 
0.42, 0.49 
0.49 0.80 
0.67, 0.94 
0.86 59.22 
55.10, 63.65 
0.23 0.59 
0.53, 0.66 
0.29 2.65 
2.37, 2.96 
0.19 
+/-  (CG) 99.23 
90.99, 108.21 
 130.82 
121.28, 141.11 
 0.48 
0.45, 0.51 
 0.81 
0.69, 0.94 
 55.74 
52.30, 59.41 
 0.65 
0.59, 0.72 
 2.98 
2.70, 3.29 
 
-/-   (GG) 94.76 
69.18, 129.81 
 143.49 
108.98, 188.93 
 0.45 
0.36, 0.57 
 0.69 
0.39, 1.20 
 66.15 
52.49, 83.37 
 0.53 
0.36, 0.76 
 2.37 
1.66, 3.39 
 
ARNT (rs2228099)              
+/+ (GG) 105.59 
94.55, 117.93 
0.20 143.30 
130.13, 157.79 
0.04 0.50 
0.46, 0.54 
0.14 0.85 
0.70, 1.04 
0.44 60.75 
56.00, 65.90 
0.24 0.64 
0.56, 0.73 
0.70 2.84 
2.51, 3.22 
0.73 
+/-  (GC) 92.80 
84.83, 101.52 
 131.28 
121.39, 141.97 
 0.45 
0.42, 0.48 
 0.81 
0.69, 0.95 
 56.63 
53.00, 60.50 
 0.60 
0.54, 0.67 
 2.74 
2.474, 3.04 
 
-/-   (CC) 96.11 
82.44, 112.03 
 115.72 
101.24, 132.28 
 0.47 
0.42, 0.52  
 0.68 
0.52, 0.90 
 54.51 
48.68, 61.03 
 0.65 
0.54, 0.78 
 2.97 
2.49, 3.53 
 
CYP1B1 (rs1800440)              
+/+ (AA) 97.00 
89.85, 104.71 
0.04 132.17 
123.61, 141.31 
0.19 0.46 
0.44, 0.49 
0.79 0.79 
0.69, 0.91 
0.98 57.90 
54.71, 61.26 
0.92 0.62 
0.56, 0.67 
0.08 2.77 
2.54, 3.03 
0.81 
+/-  (AG) 103.28 
91.55-116.51 
 136.10 
122.48, 151.26 
 0.48 
0.44, 0.52 
 0.80 
0.65, 0.99 
 56.64 
51.81, 61.92 
 0.67 
0.58, 0.77 
 2.91 
2.54, 3.34 
 
-/-   (GG) 66.41 
48.23, 91.44 
 103.27 
78.06, 136.61 
 0.44 
0.35, 0.58 
 0.75 
0.43, 1.33 
 57.00 
49.74, 72.19 
 0.43 
0.29, 0.62 
 2.68 
1.86, 3.86 
 
95% LL,UL= 95% confidence limits; lower limit, upper limit 
SHBG= sex hormone binding globulin 
SNP= single nucleotide polymorphism 
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Table 3.5: The association between combined SNPs, hormone serum concentrations, ratios and SHBG concentration 
 
Genotype Estradiol (pg/mL) 
 
 
Estrone (pg/mL) 
 
 
Testosterone 
(ng/mL) 
 
Progesterone 
(ng/mL) 
 
SHBG (nmol/L) 
 
 
Free estradiol index 
 
 
Free testosterone 
index 
 
Geometric 
mean 
95%LL, UL 
p 
value 
Geometric 
 mean 
95%LL, UL 
p 
value 
Geometric 
mean 
95%LL, UL 
p 
value 
Geometric 
mean 
95%LL, UL 
p 
value 
Geometric 
mean 
95%LL, UL 
p 
value 
Geometric 
mean 
95%LL, UL 
p 
value 
Geometric 
mean 
95%LL, UL 
p 
value 
AHR and AHRR 
+/+ and +/+ 97.75 
86.39, 110.62 
0.35 133.39 
119.74, 148.59 
0.15 0.43 
0.40, 0.48 
0.17 0.81 
0.65, 1.01 
0.50 63.41 
57.91, 69.44 
0.05 0.57 
0.49, 0.65 
0.26 2.37 
2.06, 2.72 
0.02 
+/+ and +/- 
or -/- 
100.15 
92.11, 108.90 
 136.34  
126.72, 146.68 
 0.48 
0.45, 0.51 
 0.83 
0.71, 0.96 
 56.06 
52.72, 59.62 
 0.66 
0.59, 0.72 
 2.95 
2.69, 3.25 
 
+/-, -/- and 
+/-, -/- 
87.80 
74.97, 102.81 
 116.98 
101.92, 134.28 
 0.49 
0.43, 0.55 
 0.69 
0.52, 0.91 
 54.09 
48.17, 60.74 
 0.60 
0.50, 0.72 
 3.12 
2.61, 3.73 
 
AHR and ARNT  
+/+ and +/+ 110.08 
96.53, 125.52 
0.05 149.34 
133.14, 167.50 
0.04 0.51 
0.46, 0.56 
0.04 0.88 
0.69, 1.11 
0.43 63.15 
57.33, 69.56 
0.04 0.64 
0.55, 0.75 
0.90 2.78 
2.39, 3.23 
0.12 
+/+ and +/- 
or -/- 
96.76 
88.82, 105.41 
 129.74 
120.39, 139.83 
 0.44 
0.42, 0.47 
 0.81 
0.69, 0.94 
 57.42 
53.91, 61.16 
 0.62 
0.56, 0.68 
 2.67 
2.42, 2.94 
 
+/-, -/- and 
+/-, -/- 
87.14 
76.17, 99.69 
 122.00 
08.46, 137.22 
 0.49 
0.44, 0.54 
 0.70 
0.55, 0.89 
 52.62 
47.66, 58.10 
 0.61 
0.52, 0.71 
 3.23 
2.77, 3.77 
 
AHR and CYP1B1 
+/+ and +/+ 100.75 
91.57, 110.85 
0.49 135.00 
124.19, 146.74 
0.31 0.45 
0.42, 0.49 
0.49 0.85 
0.71, 1.00 
0.62 60.42 
56.33, 64.82 
0.17 0.61 
0.55, 0.69 
0.89 2.59 
2.33, 2.89 
0.13 
+/+ and +/- 
or -/- 
96.07 
87.64, 105.32 
 132.56 
122.35, 143.64 
 0.48 
0.44, 0.51 
 0.75 
0.64, 0.89 
 55.67 
52.04, 59.56 
 0.63 
0.57, 0.71 
 2.96 
2.67, 3.29 
 
+/-, -/- and 
+/-, -/- 
87.47 
69.56, 110.01 
 114.08 
93.39, 139.36 
 0.49 
0.42, 0.58 
 0.79 
0.53, 1.19 
 53.28 
45.02, 63.06 
 0.60 
0.46, 0.79 
 3.20 
2.47, 4.16 
 
CYP1B1 and CYP1B1 (rs1056836) 
+/+ and +/+ 99.47 
87.57, 112.99 
0.81 139.35 
124.69, 155.73 
0.39 0.49 
 0.45, 0.54 
0.24 0.88 
0.70, 1.10 
0.51 56.42 
51.40, 61.93 
0.73 0.65 
0.56, 0.75 
0.58 3.03 
2.62, 3.49 
0.27 
+/+ and +/- 
or -/- 
95.00 
86.32, 104.55 
 126.65 
116.50, 137.70 
 0.45 
0.42, 0.48 
 0.74 
0.63, 0.88 
 58.80 
54.82, 63.07 
 0.59 
0.53, 0.66 
 2.63 
2.36, 2.93 
 
+/-, -/- and 
+/-, -/- 
98.67 
87.95, 110.71 
 133.04 
120.34, 147.09 
 0.47 
 0.43, 0.51 
 0.79 
0.65, 0.97 
 56.80 
52.22, 61.79 
 0.64 
0.56, 0.73 
 2.88 
2.53, 3.28 
 
95% LL,UL= 95% confidence limits ; lower limit, upper limit 
SHBG= sex hormone binding globulin 
SNP= single nucleotide polymorphism 
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CHAPTER IV 
Genetic polymorphisms in the AHR signaling pathway and sleep disturbances in midlife 
women
2
 
4.1 Abstract 
Objective: To determine whether selected genetic polymorphisms in the aryl hydrocarbon 
receptor (AHR) signaling pathway and CLOCK are associated with insomnia and early 
awakening in midlife women.  
Methods: Women aged 45 to 54 years (n=639) were recruited into a midlife health study and 
agreed to complete questionnaires and donate blood samples. Questionnaires were used to assess 
sleep outcomes. Blood samples were genotyped for the selected polymorphisms: AHR 
(rs2066853); AHR repressor (AHRR; rs2292596); aryl hydrocarbon nuclear translocator (ARNT; 
rs2228099); and CLOCK (rs1801260). Data were analyzed using multivariable logistic 
regression.  
Results: Women heterozygous for the AHRR alleles (GC) had decreased odds of insomnia 
compared to women homozygous for the AHRR_C allele (adjusted odds ratio (aOR): 0.69; 95% 
confidence interval (CI): 0.49-0.96). Women with at least one of the AHRR_G or CLOCK_C 
alleles had significantly decreased odds of insomnia compared to women homozygous for the 
AHRR_C and CLOCK_T alleles (aOR: 0.64; 95% CI: 0.43-0.96). Additionally, women 
homozygous for the AHRR_G and CLOCK_C alleles had significantly decreased odds of 
                                                          
2 Published in the Journal of Sleep Medicine 
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insomnia compared to women homozygous for the AHRR_C and CLOCK_T alleles (aOR: 0.56; 
95% CI: 0.35-0.89). None of the selected SNPs or combinations of SNPs were significantly 
associated with early awakening.  
Conclusions: Selected genetic polymorphisms in the AHR signaling pathway (i.e. AHRR) and 
CLOCK may play a role in decreasing the risk of experiencing insomnia during the menopausal 
transition.  
Key words/terms: polymorphism, CLOCK, AHR, insomnia, early awakening, midlife women 
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4.2 Introduction 
As women age and go through the menopausal transition, the likelihood of experiencing 
sleep disturbances increases [1-3].  Previous studies have examined potential factors associated 
with sleep disturbances during this time period; however, these studies mainly have focused on 
hormonal changes, vasomotor symptoms, or stress [4-8]. Though some of these factors have 
been found to be significantly associated with sleep disturbances [7, 8], the data are equivocal 
[9]. For example, sleep disturbances can be experienced by healthy women without vasomotor 
symptoms [2, 9]. Additionally, even after vasomotor symptoms have diminished, some women 
still experience sleep disturbances [9]. Similarly, women experiencing stress or altered hormonal 
levels may not have sleep disturbances. Therefore, our study focused on whether other factors, 
such as selected genetic polymorphisms, are associated with sleep disturbances during the 
menopausal transition. 
The main master regulators of circadian rhythms related to sleep/wake cycles are 
circadian locomotor output cycles kaput (CLOCK) and brain and muscle aryl hydrocarbon 
receptor nuclear translocator (ARNT)-like (BMAL1). These regulators are members of the basic 
helix-loop-helix (bHLH)/period-ARNT-single minded (PAS) domain family. These domains are 
needed for binding and transcription regulation [10]. Overall, the clock machinery acts in a 
feedback activation/inhibition manner [11]. Basically, the CLOCK/BMAL1 heterodimer 
complex binds to the enhancer boxes of their target genes and further initiates the 
transcription/translation of inhibiting factors: periods (PER 1,2, and 3) and cryptochromes 
(CRY1 and 2). This leads to increased levels of the inhibiting complexes and results in reduced 
transcription/translation. This then allows consecutive action of CLOCK and BMAL1 [11]. 
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Other members of the bHLH/PAS domain protein family belong to the aryl hydrocarbon 
receptor (AHR) signaling pathway. This highly conserved signaling pathway is present in most 
cell types. In addition, members of this pathway have a daily oscillation rhythm of their own that 
operates in a tissue specific manner in rodents [12, 13]. The main members of this signaling 
pathway are the AHR, its repressor (AHRR), and ARNT.  The bHLH/PAS domains of BMAL1 
and ARNT are extremely similar, and are thought to originate from the same ancestral gene [14]. 
Furthermore, researchers have proposed a potential functional link between the AHR signaling 
pathway and the circadian clock [15, 16]. 
Alterations in circadian rhythms, such as those resulting from genetic variations, have 
been examined by other researchers [17-19]. In a few studies, a single nucleotide polymorphism 
(SNP) in CLOCK (rs1801260; T/C) has been associated with sleep differences such as evening 
preference and delayed timing of the sleep-wake cycle [18,19]. Subjects carrying one or two 
copies of the CLOCK_C allele showed increased eveningness and reduced morningness, while 
subjects homozygous for CLOCK_T showed higher morningness scores [18,19]
 
and shorter total 
sleep duration [19].
 
The CLOCK_CC genotype was also associated with delayed sleep timing 
and greater daytime sleepiness in Japanese [19], but not in Caucasian women [18]. However, no 
studies have explored the associations between SNPs in CLOCK, the AHR pathway related 
genes, and sleep disturbances in midlife women. Hence, in our study, we tested the hypothesis 
that selected SNPs (individual and combined SNPs) in the CLOCK gene (rs1801260), and the 
AHR signaling pathway (AHR rs2066853, AHRR rs2292596, ARNT rs2228099) are associated 
with the risk of insomnia and early awakening among midlife women. 
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4.3 Materials and Methods 
Study population and design 
Study methods have been described in detail elsewhere [20, 21]. Between 2000-2004, a 
population-based cross-sectional study of midlife women’s health was conducted in the 
Baltimore metropolitan area and included 639 generally healthy women between the ages of 45-
54 years. All women from the target population were invited by mail to participate in the study. 
A woman was eligible for study participation based on age (45-54 years old), and having intact 
ovaries and uteri. Reproductive stage was based on self-reported menstrual period history and 
categorized as pre- and perimenopausal as follows: premenopausal, last menstrual period within 
the past 3 months and no changes in bleeding or regularity in the past year; perimenopausal, last 
menstrual period within the past year, but not within the past 3 months or last menstrual period 
within the past 3 months and changes in either bleeding or regularity in the past year. 
Postmenopausal women were excluded from the study.  
Women were also excluded if they were pregnant, were taking any exogenous hormones, 
or had a history of cancer. Eligible women were scheduled for a morning visit in the clinic after 
fasting overnight. At the clinic visit, participants were weighed, measured, and had their blood 
drawn for genotyping for selected SNPs. Additionally, study participants completed a detailed 
study questionnaire that included questions regarding their sleep quality, medical and family 
history, lifestyle habits, and reproductive history. All participants gave written informed consent 
according to procedures approved by the University of Illinois at Urbana-Champaign and Johns 
Hopkins University Institutional Review Boards.  
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Participants were asked if “they experienced early awakening or insomnia (difficulty 
sleeping) on a regular basis (once a week or more) anytime during a month?” Dichotomous 
sleep outcomes examined in the analyses were: experienced insomnia in the past year (yes or 
no) and experienced early awakening in the past year (yes or no).  Age and race/ethnicity were 
self-reported. Smoking status (current, former, and never) was based on participants’ answers 
to the questions: “Have you ever smoked cigarettes?” and “Do you still smoke cigarettes?” 
Lastly, body mass index (BMI) was calculated based on height and weight measurements of 
the participant at the clinic visit and categorized either as normal BMI (<25 kg/m
2
), 
overweight (25.0-29.9 kg/m
2), or obese (≥30.0 kg/m2).  
Genotyping 
Genomic deoxyribonucleic acid (DNA) was isolated from whole blood using GenElute 
Blood Genomic DNA kits (Sigma, St. Louis, MO). DNA samples were genotyped for the 
following polymorphisms: CLOCK (rs1801260; T/C), AHR (rs2066853; G/A), ARNT 
(rs2228099; G/C) and AHRR (rs2292596; C/G). DNA extracts were amplified by polymerase 
chain reactions as previously published [22,23]. Genotypes were determined based on amplicon 
size using agarose gel electrophoresis. 
Statistical analyses 
The associations between the selected genetic polymorphisms, categorical covariates, 
and sleep disturbance outcome variables were analyzed using chi-square tests. Unadjusted 
odds ratios (ORs), covariate-adjusted ORs, and 95% confidence intervals (CI) for associations 
between genetic polymorphisms, or combination of polymorphisms, and sleep disturbance 
outcome variables were generated using logistic regression models. Age, race, body mass 
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index, and smoking status were selected a-priori as variables to adjust for and, thus were 
included in all logistic regression models. Specifically, age was included because studies 
indicate that the prevalence of sleep disturbances in women increases with age [2, 4].
 
Race was 
included because it was previously reported to be associated with early awakening in midlife 
women [2].
 
Specifically, Caucasian women have been shown to have higher rates of early 
awakening compared to Hispanic women [2]. BMI was included because obesity was 
previously shown to be a risk factor of insomnia [24] and it was significantly associated with 
early awakening in our sample. Lastly, smoking status was added to the statistical model 
because our study includes selected SNPs in the AHR signaling pathway and it is well known 
that compounds present in cigarette smoke can activate the AHR signaling pathway [25]. 
Additionally, smoking status was significantly associated with insomnia and early awakening 
in our sample.  
Prior to including age, race, BMI, and smoking status in the covariate-adjusted models, 
these variables were each examined as potential effect modifiers using stratified analyses. In 
all of the stratified analyses, the resulting odds ratios did not differ in strata of the examined 
variable (strata were: age, 45 to 49 years and 50 to 54 years; race, Caucasian and African-
American; BMI, <25kg/m
2
, 25 to 29.9 kg/m
2
, and >30 kg/m
2
; smoking: ever and never). 
Therefore, none of the stratified analyses are presented. All statistical analyses were performed 
using SAS Version 9.1 (Cary, NC). A p-value of less than 0.05 was considered to be 
statistically significant. 
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4.4 Results 
Characteristics and genotype distributions of our study sample by sleep disturbance outcomes are 
presented in Table 1. Women who experienced insomnia were more likely to be current smokers 
compared to women who did not experience insomnia. Similarly, women who experienced early 
awakening were more likely to be former/current smokers, and less likely to be obese compared 
to women who did not experience early awakening. Age, race, and menopausal status 
distributions of women who experienced insomnia or early awakening were not significantly 
different than women who did not experience insomnia or early awakening.  
        We used the Hardy-Weinberg equation to estimate if the observed genotype frequencies in 
our study sample differed from the predicted genetic variation at equilibrium of the general 
population. Only the ARNT genotype distribution met the assumptions of the Hardy Weinberg 
Equilibrium Theory (p=0.54), while AHR, AHRR, and CLOCK did not meet these assumptions 
(p= 0.012, 0.0001, and 0.04, respectively). This indicates a stable frequency distribution of ARNT 
in our study compared to the predicted variation of the general population and that evolutionary 
mechanisms may operate on the loci of the other selected genes. 
         Women who experienced insomnia were less likely to carry the AHRR_G compared to 
women who did not experience insomnia. However, the genotype distribution of AHR, ARNT, 
and CLOCK did not differ in women with or without insomnia. Additionally, the percentages of 
women with genetic polymorphisms in AHRR, AHR, ARNT, and CLOCK were not significantly 
different between women who experienced early awakening and women who did not experience 
early awakening. 
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The unadjusted and covariate-adjusted associations between the selected polymorphisms 
and insomnia and early awakening are presented in Table 2. The selected SNP in AHRR was 
associated with insomnia after adjusting for age, BMI, race, and smoking status. Specifically, 
women heterozygous for the AHRR alleles (CG) had lower odds of insomnia compared to 
women homozygous for the AHRR_C allele [adjusted odds ratio (aOR): 0.69; 95% confidence 
interval (CI): 0.49-0.96]. SNPs in AHR, ARNT and CLOCK were not associated with insomnia. 
None of the SNPs (i.e. AHRR, AHR, ARNT, or CLOCK) were associated with early awakening.  
The associations between combinations of SNPs and insomnia or early awakening are 
presented in Table 3. The combined SNPs of CLOCK and AHRR were significantly associated 
with insomnia. Specifically, women heterozygous for one of the following alleles CLOCK_C or 
AHRR_G had lower odds of experiencing insomnia (aOR: 0.64; 95% CI: 0.43-0.96) compared to 
women homozygous for CLOCK_T and AHRR_C. Similarly, women who carried both of the 
alleles of CLOCK_C and AHRR_G had decreased odds of experiencing insomnia (aOR 0.56; 
95% CI: 0.35-0.89) compared to women homozygous for CLOCK_T and AHRR_C. 
Additionally, the combined SNPs of CLOCK and ARNT were significantly associated with 
insomnia only in the crude analysis and no longer significant after adjusting for the covariates. 
Women heterozygous for one of the CLOCK_C or ARNT_C alleles had decreased odds of 
insomnia compared to women homozygous for the CLOCK_T and ARNT_G alleles (OR: 0.62; 
95% CI: 0.41-0.95). In contrast, the combined SNPs of CLOCK and AHR had similar odds of 
insomnia for all genotypes. Further, none of the combined SNPs of CLOCK and AHRR, ARNT, 
or AHR were significantly associated with early awakening.  
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4.5 Discussion 
This study examined the relationship between genetic polymorphisms in the AHR 
signaling pathway, the CLOCK gene, and two common sleep disturbance outcomes: insomnia 
and early awakening. Findings from this study suggest a potential role of the AHR signaling 
pathway in experiencing insomnia during midlife. The AHR signaling pathway may act alone or 
in combination with CLOCK. 
In our study, the AHRR was associated with insomnia. At a cellular level, there is a 
relationship of regulator-activator between the AHRR and the AHR. Interestingly, in our study, 
the AHRR was significantly associated with a decreased risk of insomnia. Since the AHRR plays 
a role as a repressor of the AHR by competitive binding with ARNT, it is possible that the 
AHRR acts on circadian rhythm components such as BMAL1 that serves as a key regulator 
(along with PER1) in circadian rhythms. The BMAL1/CLOCK complex forms a positive 
element of the transcriptional-translational feedback loop that activates the expression of PER 
and CRY genes. The PER/CRY complex leads to the inhibition of BMAL1/CLOCK activity. We 
can only speculate that women heterozygous for the selected SNP in the AHRR have an altered 
feedback transmission to the PER/CRY leading to delayed inhibition of BMAL1/CLOCK 
activity. 
Though the CLOCK gene plays a central role in circadian rhythm regulation, the selected 
SNP of CLOCK (rs1801260) was not associated with insomnia or early awakening. While 
previous studies have examined the association between CLOCK and sleep outcomes, they have 
not focused on insomnia or early awakening. Mishima et al. [19] reported a significant 
association between the homozygosity of the CLOCK_C allele and shorter sleep time. In 
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contrast, Robilliard et al. [17]
 
found no significant association between the selected CLOCK SNP 
and morning or evening preference. Currently, the biological effects of this SNP on the 
functionality or stability of the genomic sequences are unknown. Thus, it is unclear why the 
selected CLOCK polymorphism is associated with some sleep outcomes (e.g. shorter sleep time), 
but not all (morning/evening preference, insomnia, early awakening). It may also be that 
CLOCK interacts with factors that regulate sleep or sleep related processes that were not fully 
explored in our study. 
Further, it may also be that CLOCK interacts with other factors in the AHR signaling 
pathway (as we observed in the current study). Specifically, our results suggest that the CLOCK 
polymorphism may affect sleep outcomes when combined with other SNPs (such as AHRR or 
ARNT).  Importantly, the combined SNPs of CLOCK_C and AHRR_G maintain the same 
statistical effect as the AHRR alone (i.e. decreased odds of insomnia). Hence, it is possible that 
the AHRR acts directly on CLOCK and not only on BMAL1. Future studies in other populations 
along with mechanistic studies should explore whether CLOCK moderates the association 
between the AHR signaling pathway and sleep disturbances despite having no independent main 
effect. 
Overall findings from our current study, along with previous publications [10, 26, 27, 
28], are highly suggestive for involvement of the AHR signaling pathway in the regulation of 
circadian rhythmicity. Our current study has several strengths. It is innovative in its research 
approach and the examined study questions. In addition, we studied a sample of generally 
healthy women during their menopausal transition, a time in which many women start suffering 
from sleep disturbances. Despite these strengths, we were able to examine only a limited number 
of SNPs and two sleep outcomes. Hence, it is possible that the selected SNPs are significantly 
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associated with other sleep disturbance outcomes (e.g. hypersomnia, sleep quality, and daytime 
sleepiness). It is also possible that other SNPs in the genes that we investigated may also be 
associated with insomnia or early awakening. Lastly, the sleep outcomes were subjective and did 
not include levels/degrees of sleep disturbance.  
In conclusion, our results suggest that the AHR signaling pathway may act with known 
regulators in sleep/awake rhythms to alter the risk of insomnia. Further studies should investigate 
the potential roles of individual SNPs as well as combinations of the selected SNPs to obtain a 
better understanding of their potential role as risk factors for sleep disturbances during the 
menopausal transition. 
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4.6 Tables   
Table 4.1: Sample characteristics 
 Insomnia p value Early awakening p value 
(n) No (344) Yes (288)  No (330) Yes (307)   
Age n (%)   0.44   0.81 
45 to 49 218 (53.3) 191 (46.7)  212 (51.5) 200 (48.5)  
50 to 54 126 (56.5) 97 (43.5)  118 (52.4) 107 (47.6)  
Race n (%)   0.38   0.56 
Caucasian 282 (53.7) 243 (46.3)  280 (52.6) 252 (47.4)  
African American 54 (57.4) 40 (42.6)  44 (47.3) 49 (52.7)  
Other 8 (72.7) 3 (27.3)  6 (60.0) 4 (40.0)  
BMI n (%)    0.06   0.04 
<25.0 kg/m
2
 158 (58.1) 114 (41.9)  85 (45.0)  104 (55.0)  
25.0 to 29.9 kg/m
2
  97 (56.7) 74 (43.3)  90 (51.7) 84 (48.3)  
≥30 kg/m2 89 (47.3) 99 (52.7)  155 (56.8)  118 (43.2)  
Smoking status n 
(%) 
  0.04   0.04 
Never  189 (57.6)  139(42.4)   186 (56.0) 146 (44.0)  
Former  132 (53.9)  113 (46.1)  120 (48.8)  126 (51.2)  
Current    23 (39.7)  35 (60.3)     23 (39.7) 35 (60.3)  
Menopausal status n 
(%) 
  0.70   0.20 
Pre-menopause  133 (55.9)  105 (44.1)   133 (55.6) 106 (44.4)  
Peri-menopause  207 (54.2)  175 (45.8)  194 (50.3)  192 (49.7)  
AHRR n (%)   0.03   0.37 
CC 137 (51.3) 130 (48.7)  140 (52.6) 126 (47.4)  
CG 197 (58.5) 140 (41.5)  180 (52.5) 163 (47.5)  
GG  9 (34.6)  17 (65.4)  10 (38.5)  16 (61.5)  
AHR n (%)   0.20   0.12 
GG 238 (55.2) 193 (44.8)  237 (54.7) 196 (45.3)  
GA 93 (55.4) 75 (44.6)  79 (45.9) 93 (54.1)  
AA  12 (38.7)  19 (61.3)   14 (46.7)  16 (53.3)  
ARNT n (%)   0.73   0.96 
GG 108 (52.7) 97 (47.3)  108 (51.4) 102 (48.6)  
CG 173 (54.6) 144 (45.4)  167 (52.5) 151 (47.5)  
CC 62 (57.4) 46 (42.6)  55 (51.4) 52 (48.6)  
CLOCK n (%)   0.32   0.17 
TT 191 (51.9) 177 (48.1)  192 (52.0) 177 (48.0)  
TC 139 (58.2) 100 (41.8)  130 (53.5) 113 (46.5)  
CC  13 (54.2)  11 (45.8)   8 (33.3)  16 (66.7)  
    Abbreviations: BMI, body mass index; AHRR, aryl hydrocarbon receptor repressor; AHR,  
    aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor translocator; CLOCK, circadian  
      locomotor output cycles kaput. 
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 Table 4.2: Associations between selected SNPs and sleep outcomes 
 Insomnia Early awakening 
 Unadjusted 
model 
Adjusted model Unadjusted 
model 
Adjusted model 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
AHRR          
CC 
 
1.00 Referent  1.00 Referent  1.00 Referent  1.00 Referent 
CG  0.75 0.54-1.04  0.69 0.49-0.96  1.01 0.73-1.39  1.02 0.73-1.43 
GG  1.99 0.86-4.62  1.63 0.68-3.88  1.78 0.78-4.06  1.70 0.73-3.96 
AHR         
GG 
 
1.00 Referent 
 
1.00 Referent 
 
1.00 Referent 
 
1.00 Referent 
GA  0.99 0.70-1.42  1.06 0.72-1.57  1.42 1.00-2.03  1.36 0.93-2.01 
AA  1.95 0.93-4.12  2.19 0.99-4.85  1.38 0.66-2.90  1.32 0.61-2.85 
ARNT          
GG 
 
1.00 Referent 
 
1.00 Referent 
 
1.00 Referent 
 
1.00 Referent 
CG  0.93 0.65-1.32  0.96 0.67-1.37  0.96 0.68-1.36  0.97 0.68-1.38 
CC  0.83 0.52-1.32  0.85 0.53-1.38  1.00 0.63-1.60  0.97 0.61-1.56 
CLOCK          
TT  1.00 Referent  1.00 Referent  1.00 Referent  1.00 Referent 
TC  0.78 0.56-1.08  0.75 0.54-1.06  0.94 0.68-1.30  0.96 0.69-1.34 
CC  0.91 0.40-2.09  0.83 0.35-1.94  2.17 0.91-5.19  2.20 0.91-5.33 
Abbreviations: BMI, body mass index; AHRR, aryl hydrocarbon receptor repressor; AHR, aryl 
hydrocarbon receptor; ARNT, aryl hydrocarbon receptor translocator; CLOCK, circadian 
locomotor output cycles kaput. 
Adjusted OR is adjusted for age (45-49 years or 50-55 years), race, body mass index (≥30, 25-
29, <25), and smoking status (never, former, and current) 
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Table 4.3: Associations between combinations of the selected SNPs and sleep outcomes 
 Insomnia Early awakening 
 Unadjusted model Adjusted model Unadjusted model Adjusted model 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
CLOCK and AHRR 
CLOCK _TT+ 
AHRR_CC 
1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 
Carriers of CLOCK_T 
or AHRR_G 
0.71 0.49-1.04 0.64 0.43-0.96 0.97 0.66-1.42 0.99 0.67-1.47 
Carriers of CLOCK_T 
and AHRR_G 
0.64 0.41-1.01 0.56 0.35-0.89 1.07 0.69-1.66 1.10 0.69-1.74 
CLOCK and ARNT 
CLOCK _TT+ 
ARNT_GG 
1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 
Carriers of CLOCK_T 
or ARNT_C 
0.62 0.41-0.95 0.66 0.43-1.01 0.88 0.58-1.33 0.92 0.60-1.41 
Carriers of CLOCK_T 
and ARNT_C 
0.67 0.42-1.07 0.67 0.42-1.09 0.97 0.61-1.53 0.99 0.62-1.59 
CLOCK and AHR 
CLOCK _TT+ 
AHR_GG 
1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent 
Carriers of CLOCK_T 
or AHR_G 
0.90 0.64-1.26 0.95 0.67-1.34 1.36 0.97-1.91 1.38 0.98-1.96 
Carriers of CLOCK_T 
and AHR_A 
0.87 0.51-1.47 0.82 0.47-1.43 1.31 0.78-2.19 1.20 0.70-2.05 
Abbreviations: BMI, body mass index; AHRR, aryl hydrocarbon receptor repressor; AHR, aryl hydrocarbon receptor; 
ARNT, aryl hydrocarbon receptor translocator; CLOCK, circadian locomotor output cycles kaput. 
Adjusted OR is adjusted for age (45-49 years or 50-55 years), race, body mass index (≥30, 25-29, <25), and smoking 
status (never, former, and current) 
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CHAPTER V 
Bisphenol A inhibits cultured mouse ovarian follicle growth partially via the aryl 
hydrocarbon receptor signaling pathway
3
 
 
5.1 Abstract 
Bisphenol A (BPA) is an endocrine disruptor that inhibits growth of mouse ovarian follicles and 
disrupts steroidogenesis at a dose of 100 μg/ml. However, the effects of lower doses of BPA and 
its mechanism of action in ovarian follicles are unknown. We hypothesized that low doses of 
BPA inhibit follicular growth and decrease estradiol levels through the aryl hydrocarbon receptor 
(AHR) pathway. Antral follicles from wild-type and Ahr knock-out (AhrKO) mice were cultured 
for 96 hours. Follicle diameters and estradiol levels then were compared in wild-type and AhrKO 
follicles ± BPA (0.001-100 μg/ml). BPA inhibited follicle growth (25-100 μg/ml) and decreased 
estradiol levels (10-100 μg/ml) in wild-type and AhrKO follicles. However, at BPA 25 μg/ml, 
inhibition of growth in AhrKO follicles was attenuated compared to wild-type follicles. These 
data suggest that BPA inhibits follicle growth partially via the AHR pathway, whereas its effects 
on estradiol synthesis likely involve other mechanisms. 
 
Key words: BPA, AHR, antral follicle, ovary, low dose, estradiol 
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5.2 Introduction 
Antral follicles are the most mature types of mammalian ovarian follicles. They are essential 
for reproduction and endocrine homeostasis because they are the only follicle type capable of 
ovulation and they are the main source of estradiol production in the female body. Alterations in 
proper growth or function of the antral follicles may result in infertility. While there are many 
causes of infertility, environmental chemical exposures may lead to impaired follicular growth 
and reduced estradiol levels, and in turn, lead to infertility. 
Bisphenol A (BPA) is a chemical widely used by plastic and epoxy resin manufacturers. It is 
incorporated in numerous products such as plastic containers, toys, building materials, and the 
lining of metal cans such as those used for food and baby formulas [1]. Unfortunately, BPA can 
leach out of the products it is incorporated in
 
and end up in food and beverages [1]. Several 
studies indicate that BPA is detectable in different human tissues and fluids, including ovarian 
follicular fluid [2]. These findings are of concern because BPA is known to have endocrine 
disrupting properties and to be a reproductive toxicant [3]. For example, BPA exposure has been 
associated with adverse reproductive outcomes such as infertility [4, 5] and polycystic ovarian 
syndrome in women [6]. Further, postnatal exposure to BPA (150 μg/pup of 1.5 gram body 
weight) causes polyovular follicles in mice [7]. In vitro treatment with BPA (1 µM) causes 
proliferation of MCF-7 cells [8] and decreases viability of mouse granulosa cells (BPA 100 pM-
100 µM) [9]. Recently, BPA has been shown to have toxic effects on cultured mouse ovarian 
follicles [10-12]. Specifically, BPA at 100 μg/ml inhibits growth of mouse antral follicles and 
BPA at 10 or 100 μg/ml decreases estradiol synthesis compared to vehicle control treated 
follicles [10].
 
However, not many studies have examined the effects of BPA on ovarian follicles 
using a wide dose range. Thus, one goal of the current study was to examine the effects of a wide 
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range of doses of BPA (0.001-100 μg/ml) on ovarian follicle function by focusing on follicle 
growth and estradiol levels. Since it has been suggested that BPA may act in a non-monotonic 
manner [13], we specifically tested the hypothesis that a wide range of BPA doses causes U-
shaped dose-response effects on follicle growth and estradiol levels.  
Though BPA has been shown to act on various tissues and cell types such as MCF-7 cells 
[14],
 
adipose tissue [15], and pituitary cell lines [16], the receptor types that mediate the effects 
of BPA on ovarian follicles have not been determined yet. A few studies have focused on 
whether BPA exerts its action through nuclear receptors such as estrogen [14], androgen [17], 
and thyroid [18, 19] receptors. Further, Peretz et al. [11]
 
have shown that BPA does not exert its 
toxic effects via the genomic estrogenic pathway in mouse ovarian follicles. Thus, another goal 
of this study was to determine if BPA exerts its toxicity in mouse antral follicles via the aryl 
hydrocarbon receptor (AHR) pathway. 
 
We focused on the AHR pathway because it mediates the effects of various 
environmental chemicals, including its most potent ligand 2,3,7,8,- tetrachlorodibenzo-p-dioxin 
(TCDD) [20]. Upon ligand binding, cytoplasmic AHR enters the nucleus, partners with its 
translocator (AHR nuclear translocator; ARNT), and binds to specific DNA response elements, 
leading to transcription of several genes including cytochrome P450, family 1, subfamily b, 
polypeptide 1 (Cyp1b1). Further, the AHR repressor (AHRR) can heterodimerize with ARNT to 
terminate the activation of the AHR signaling pathway [21-23].  
We also focused on the AHR because it plays a central role in the ovary [24]. For 
example, the AHR is involved in regulating the growth of pre-antral and antral follicles by 
increasing granulosa cell proliferation [25]. It is also involved in regulation of estradiol 
production by the ovary [26]. However, previous studies that have examined the potential role of 
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the AHR in mediating the toxic effects of BPA have been equivocal. For example, Nishizawa et 
al. [27] reported that following in utero exposure to BPA, Ahr expression was elevated in the 
gonads harvested from embryos, whereas Bonefeld-Jorgensen et al. [28] reported weak 
antagonistic effects of BPA with the AHR (AHR-CALUX system; mouse hepatoma cell line).  
Nevertheless, no study has examined the direct role of the AHR in mediating the toxic 
effects of BPA on ovarian follicles. Thus, another goal of the current study was to test the 
hypothesis that the AHR mediates the toxic effects of BPA on the growth of cultured mouse 
antral follicles. Specifically, we hypothesized that BPA exposure leads to changes in the 
expression of main factors in the AHR signaling pathway in antral follicles isolated from wild-
type (WT) mice, and that the effects of BPA exposure on the growth of antral follicles are 
attenuated in follicles lacking the AHR (i.e., follicles isolated from AHR global knock-out mice; 
AhrKO) compared to WT follicles.  
Lastly, activation of the AHR signaling pathway can decrease the levels of estradiol 
synthesizing enzymes and increase the levels of estradiol metabolizing enzymes (e.g., CYP1B1) 
[29]. For example, Karman et al. [30]
 
found that exposure of cultured mouse antral follicles to 
various doses of the potent AHR ligand TCDD decreased estradiol levels compared to control 
follicles. Interestingly, Peretz et al. [10] reported that antral follicles cultured with BPA (10, 100 
μg/ml) also synthesized lower estradiol levels compared to control follicles. Thus, it is possible 
that the AHR mediates the toxic effects of BPA on mouse antral follicles by decreasing estradiol 
levels. Therefore, a final goal of this study was to test the hypothesis that treatment of cultured 
mouse antral follicles with BPA leads to lower estradiol levels via mechanisms involving the 
AHR signaling pathway. 
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5.3 Materials and methods 
Chemicals 
BPA powder (99%) was purchased from Sigma-Aldrich (St. Louis, MO). Stock solution 
of BPA was prepared using dimethyl sulfoxide (DMSO) (Sigma-Aldrich) as a solvent to achieve 
a BPA dose of 133 mg/ml (438 μM). Further dilutions of the stock solution with DMSO 
generated working dilutions of 0.001, 0.013, 0.133, 1.33, 13.3, 33.3, and 66.5 mg/ml 
(approximately equivalent to 0.004, 0.04, 0.44, 4.38, 43.8, 110, and 219 μM, respectively). These 
serial dilutions allowed us to add an equal volume of BPA to each individual well in which a 
follicle was placed, and to control for solvent concentration. Final concentrations of BPA in 
culture were 0.001, 0.01, 0.1, 1.0, 10, 25, 50, and 100 μg per 1 ml of culture supplemented 
media. 
The selected dose range is based on previous findings and environmentally relevant 
levels [31, 32]. Previous studies indicate that BPA at 1, 10, and 100 μg/ml exhibited a selective 
inhibition of growth of follicles isolated from Friend leukemia virus B (FVB) mice (30-32 days 
old) [10]. Specifically, BPA at 100 μg/ml, but not at 1 and 10 μg/ml doses inhibited follicle 
growth starting at 72 hours and continuing for 96 hours of culture. Therefore, BPA at 1, 10, 100 
μg/ml was included in this study. Additionally, a wide range of other doses (0.001-50 μg/ml) 
were included to fully understand the dose response effects of BPA on ovarian follicles. BPA at 
0.001 μg/ml represents BPA levels that have been detected in women’s follicular fluid (i.e., 
0.001-0.002 μg/ml) [2]. Lastly, BPA at 25 μg/ml was used as a transition dose between the 
relatively low doses of BPA (up to 10 μg/ml) to the higher doses (greater than 10 μg/ml).  
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Animals 
Cycling wild-type (WT) female C57BL/6 mice were obtained from Charles River 
Laboratories (Charles River, CA). AhrKO mice (official symbol Ahr
tm1Bra
) were in a C57BL/6 
background and were originally generated by Schmidt et al. [33]. The AhrKO (Ahr
−/−
) mice used 
in each experiment were generated by intercrossing either heterozygous (Ahr
+/−
) female and male 
mice or heterozygous Ahr
+/−
 female mice with AhrKO (Ahr
−/−
) male mice. Mouse genetic 
screening was performed using ear tissue punches as previously described [34]. All mice were 
housed and bred in the core animal facility located at College of Veterinary Medicine, University 
of Illinois. Mice were maintained in polystyrene cages. Additionally, mice were kept under a 
12L:12D photoperiod, at temperature of 22±1°C, with 35% ± 4% relative humidity. Food and 
water were provided ad libitum. Mice were euthanized at 50-54 days of age by carbon dioxide 
inhalation followed by cervical dislocation. This age range was selected because previous studies 
indicate that at this age, WT antral follicles and AhrKO antral follicles have similar growth 
patterns, estradiol levels, and expression levels of a major cell cycle regulator Ccnd2 [35]. All 
procedures and experimental methods involving animals were approved by the University of 
Illinois Institutional Animal Care and Use Committee.  
Follicle Culture 
Ovaries were removed and antral follicles were mechanically isolated using fine 
watchmaker forceps and a dissecting microscope. We obtained 15-40 antral follicles with 
relative sizes of 200-400 μm from each mouse. Following isolation, follicles were placed in 
individual wells of 96-well culture plates covered with 75 μl of unsupplemented alpha Minimal 
Essential Media (α-MEM; Invitrogen, Carlsbad, CA) prior to treatment as previously described 
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[36]. At least eight follicles per treatment group were randomly placed into each treatment group 
for equal distribution between all treatment groups. After plating, follicles were treated with 150 
μl of supplemented media with vehicle control (DMSO) or BPA (0.001, 0.01, 0.1, 1.0, 10, 25, 
50, and 100 μg/ml). Supplemented media contained unsupplemented α-MEM, 1% ITS (10 ng/ml 
insulin, 5.5 ng/ml transferrin, and 5.5 ng/ml selenium; Sigma-Aldrich, St. Louis, MO), 5% fetal 
bovine serum (Atlanta biological, Lawrenceville, GA), 100 U/ml penicillin (Sigma-Aldrich), 100 
mg/ml streptomycin (Sigma-Aldrich), and 5 IU/ml human recombinant follicle stimulating 
hormone (Dr A. F. Parlow, National Hormone and Peptide Program, Harbor- UCLA Medical 
Center, Torrance, CA). An equal volume of BPA or DMSO (0.75 μl of treatment per 1 ml of 
media) was added to supplemented α-MEM to keep vehicle concentration at a constant of 
0.075% for each treatment. Follicles then were incubated for up to 96 hours, while supplying 5% 
CO2 at 37°C. 
Analysis of follicular growth 
As a measurement of growth, follicle diameter was measured on perpendicular axes 
every 24 hours. Measurements were done with an inverted microscope equipped with a 
calibrated ocular micrometer. Follicle diameters were averaged and converted to percent change 
relative to baseline (0 hour, set as 100%). Data were plotted and statistically analyzed to compare 
the effects of BPA treatments on growth compared to DMSO per time point. At least three 
separate cultures were conducted per treatment group. 
Gene expression analyses 
At the end of each culture (either 24 hours or 96 hours), follicles were immediately snap 
frozen and stored at -80
°
C until further processed for quantitative real-time polymerase chain 
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reactions (qPCR). Total RNA was extracted from pooled follicles using RNeasy Micro Kit 
(Qiagen Inc., CA) following the manufacturer’s protocol. The RNA concentration of each 
sample was determined at 260 nm using a Nanodrop ND1000 UV-Vis spectrophotometer 
(Nanodrop Technologies, Wilmington, DE). Total RNA was reversed transcribed using an 
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) according to the manufacturer’s 
instructions. Each cDNA sample was diluted 1:4 with nuclease-free water prior to further 
analyses. 
Primer sets were either based on previous publications: Ahr [30], beta actin (Actb) [30], 
Cyp1b1 [30], Arnt [37], B cell leukemia/lymphoma 2 (Bcl2) [38], BCL2-associated X protein 
(Bax) [38]
 
and BCL2-associated agonist of cell death (Bad) [38] or originally designed (Ahrr, 
NM_009644.2) using a BLASTN search that was performed in GenBank to ensure that primers 
were unique to the gene of interest and that they spanned a large intron-exon junction. The 
sequences for the originally designed Ahrr primers were: forward 5’-AGA GCT GTG TCC CCA 
GGG AAG T - 3’ and reverse 5’- CAG TGA GGA AAG ATG GCT TGT AGG - 3’.  
 All gene expression analyses were performed using the CFX96 Real-time PCR Detection 
System C1000 Thermal Cycler (Bio-Rad). All qPCR reactions were done in triplicate in a total 
volume of 10 μl per sample accordingly: 1μl of diluted cDNA, 1μl of gene specific primer mix 
(500 nM; Integrated DNA Technologies, INC., Coralville, IA), 3 μl of nuclease free water, and 5 
μl of SsoFast EvaGreen Supermix (Bio-Rad). The protocol for the qPCR runs included the 
following steps: initial denaturation of the cDNA and enzyme activation at 95°C for 1 min, 
followed by 40 cycles of 10 sec at 95°C, 10 sec at 60°C, and a fluorescent absorbance reading 
and one final annealing/elongation step for 5 min at 72°C. A heat dissociation curve (from 65°C 
to 95°C with a fluorescent absorbance reading after each 0.5°C increment) was performed at the 
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end of every run to confirm specificity of each primer pair for the chosen transcript of interest. A 
standard curve was generated from six serial dilutions of a sample representing the treatment 
groups to calculate the amplification efficiencies of each primer set. Expression data were 
generated using the mathematical model developed by Pfaffl
511
. The housekeeping gene Actb 
was used as a reference gene for each sample because there were no statistical differences in the 
expression of this gene between any of the treatment groups, including DMSO (data not shown). 
Mean relative mRNA expression ratios from 3-4 separate follicle culture experiments were 
reported.  
Measurement of estradiol levels 
The media from follicles in each treatment group were collected at the end of the 
cultures, and stored at -80
0
C until performing measurements of estradiol levels. Randomly 
selected media samples per treatment group were subjected to enzyme linked immunosorbent 
assays (ELISA) for estradiol levels according to the manufacturer’s guidelines (DRG 
International, Mountainside, NJ). The minimum detection limits were 9.71 pg/ml, and intra-assay 
and inter-assay coefficients of variation were 4.7%, and 7.8%, respectively. Individual follicle 
estradiol level was normalized to follicle diameter. Averaged estradiol levels represent 
normalized values from 12 individual follicles per treatment group obtained from three separate 
culture experiments.  
Statistical analyses 
Data were expressed as the mean ± SEM from at least three separate experiments. 
Differences between DMSO and treatment groups were statistically analyzed using SPSS 
software (SPSS Inc., Chicago, IL). For all comparisons, statistical significance was assigned at 
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p≤0.05. Treatment group data were statistically compared to DMSO control data. When data 
were normally distributed and the homogeneity of variance assumption was met, we used the 
one-way analysis of variance (ANOVA) test followed by a Dunnett’s post hoc test. When data 
were not normally distributed and/or when the homogeneity of variance assumption was not met, 
we used Kruskal-Wallis non-parametric test, followed by a Mann-Whitney test.  
5.4 Results 
Effect of BPA exposure on antral follicle growth in WT follicles (C57BL/6) 
The results indicate that BPA selectively inhibited the growth of cultured WT antral 
follicles (Figure 5.1). Specifically, doses of BPA up to 10 μg/ml did not alter follicle growth 
compared to DMSO, whereas doses of BPA from 25-100 μg/ml significantly inhibited follicle 
growth, starting at 24 hours (50, 100 μg/ml) or 48 hours (25 μg/ml) and continuing throughout 
the culture (Figure 5.1).  
Effect of BPA exposure on estradiol levels in WT follicles 
Previous studies indicate that BPA exposure at 10 and 100 μg/ml decreases estradiol 
levels in mouse antral follicle cultures [10]. Therefore, we compared estradiol levels in the media 
from vehicle and BPA-treated follicles to expand our knowledge about potential effects of a wide 
range of BPA treatments on estradiol levels. The results indicate that 96 hours exposure to BPA 
at 10, 25, 50, and 100 μg/ml significantly decreased estradiol levels synthesized by WT antral 
follicles compared to WT follicles treated with DMSO (Figure 5.2). In contrast, exposure to BPA 
at 0.001, 0.01, 0.1, and 1 μg/ml did not alter estradiol levels synthesized by WT antral follicles 
compared to WT follicles treated with DMSO (Figure 5.2). 
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Effect of BPA exposure on expression levels of Bcl2, Bax, and Bad in WT follicles 
Inhibition of follicle growth and low estradiol levels can be a result of underlying atresia 
(programmed cell death of the ovarian cells). Further, previous studies indicate that BPA at 100 
μg/ml increases expression of apoptotic factors [11]. Thus, we measured selected apoptotic 
factors levels at 96 hours in the current study. The results indicate that at 96 hours, BPA at 10 
and 25 μg/ml significantly up-regulated expression levels of the anti-apoptotic factor Bcl2 in WT 
follicles compared to DMSO treated WT follicles (Figure 5.3). In contrast, BPA did not alter the 
expression of the pro-apoptotic factors Bax or Bad at any dose compared to DMSO (data not 
shown).  
Effect of BPA exposure on expression of factors in the AHR signaling pathway in WT follicles 
To determine the potential role of the AHR in mediating the toxic effects of BPA, we 
compared relative mRNA levels of selected genes in the AHR signaling pathway (Ahr, Ahrr, 
Arnt, and Cyp1b1) in DMSO and BPA treated WT follicles. Because we observed inhibition of 
follicle growth beginning at 24 hours with BPA 50 and 100 μg/ml compared to control and 
because this inhibition continued for 96 hours, we compared expression levels at 24 and 96 hours 
per treatment group. After 24 hours of culture, BPA at 50 μg/ml significantly down-regulated 
Cyp1b1 levels in WT follicles and BPA 25 μg/ml exposure resulted in a trend toward reducing 
Cyp1b1 levels in WT follicles compared to DMSO treated WT follicles (Figure 5.4a). BPA at 0.1 
μg/ml significantly down-regulated Arnt levels in WT follicles compared to DMSO treated WT 
follicles (Figure 5.4b). However, none of the selected doses of BPA altered the expression of Ahr 
or Ahrr in WT follicles compared to DMSO treated WT follicles (Figure 5.4c, d). Similarly, at 
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96 hours, none of the selected doses of BPA altered the expression of Cyp1b1, Ahr, Ahrr, and 
Arnt in WT follicles compared to DMSO treated WT follicles (Figure 5.5a-d).  
Effect of BPA exposure on antral follicle growth in AhrKO follicles 
As a direct way to investigate the role of the AHR as a potential mediator of the toxic 
effects of BPA, we cultured follicles from AhrKO mice with a wide range of doses of BPA and 
measured their growth over time.  The data indicate that BPA at doses between 0.01-10 μg/ml 
did not alter the growth of AhrKO follicles compared to DMSO treated AhrKO follicles (Figure 
5.6). This growth pattern was similar to the growth of WT follicles following treatment with 
BPA at doses between 0.01-10 μg/ml (Figure 5.1). BPA at doses of 50 and 100 μg/ml 
significantly inhibited the growth of AhrKO follicles compared to AhrKO follicles treated with 
DMSO starting at 24 hours, and continuing throughout the culture time (Figure 6). Again, these 
results are similar to what was observed with the WT follicles at the same doses (Figure 1). 
Lastly, BPA at 25 μg/ml inhibited the growth of AhrKO follicles compared to AhrKO follicles 
treated with DMSO at 48 hours only (Figure 6). Interestingly, BPA at 25 μg/ml did not 
significantly alter the growth of AhrKO follicles compared to AhrKO follicles treated with 
DMSO at any of the other time points (Figure 6). These results are different than what we 
observed with WT follicles treated with BPA 25 μg/ml, in which inhibition of growth started at 
48 hours, but lasted throughout the culture time (Figure 5.1).  
Effect of BPA exposure on estradiol levels in AhrKO follicles 
Previous studies indicate that BPA exposure at 10 and 100 μg/ml decreases estradiol 
levels in mouse antral follicle cultures [10], but the mechanism by which BPA leads to decreased 
estradiol synthesis is unknown. Therefore, we measured estradiol levels in the media from 
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vehicle and BPA-treated AhrKO follicles to expand our knowledge about the potential role of the 
AHR signaling pathway in mediating BPA toxic effects on estradiol synthesis. The results 
indicate that 96 hours exposure to BPA at 10, 25, 50, and 100 μg/ml significantly decreased 
estradiol levels synthesized by AhrKO antral follicles compared to AhrKO follicles treated with 
DMSO (Figure 5.7). In contrast, exposure to BPA at 1 μg/ml did not alter estradiol levels 
synthesized by AhrKO antral follicles compared to AhrKO follicles treated with DMSO (Figure 
5.7). These results are similar to the results of WT follicles treated with these doses of BPA (see 
Figure 5.2). 
5.5 Discussion 
The current study expands on the limited published data regarding the direct toxic effects 
of a wide dose range of BPA on cultured mouse antral follicles. It also provides information on 
the potential mechanism by which BPA may exert its toxic effects in antral follicles. In this 
study, we utilized a follicle culture system to closely examine the direct effects of exposure to a 
wide range of doses of BPA, including environmentally relevant doses, on antral follicles [2, 11, 
12, 35]. We also compared the growth of antral follicles isolated from WT and AhrKO mice to 
examine the role of the AHR in mediating the toxic effects of BPA. The results suggest that BPA 
inhibits the growth and decreases estradiol levels of WT follicles in a dose dependent manner. 
Furthermore, the data suggest that BPA at 25 μg/ml selectively acts through the AHR signaling 
pathway to exert its toxic effects.  
BPA inhibited the growth of WT follicles at doses of 25, 50, and 100 μg/ml, but not at 
doses of 10 μg/ml or less. These findings indicate that in our antral follicle bioassay, BPA has a 
linear dose-response effect on follicular growth. This finding is in contrast to our original 
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hypothesis that BPA exhibits non-monotonic effects on follicles as it does in other cell 
lines/tissues such as pituitary cell lines [39] and adipose explants [15]. The reasons for different 
dose-response effects with BPA are unknown, but studies have shown that BPA can act 
differently in different tissues and this appears to be the case with ovarian follicle cultures versus 
pituitary cell lines and adipose explants [15, 39]. Yet, our findings are in agreement with other 
studies that examined the effects of BPA on mouse ovarian follicles. Xu et al. [9] observed that 
BPA in a dose dependent manner decreases viability of mouse cultured granulosa cells. 
Specifically, treatment with doses of 0.1 nM, 0.1 μM, and 100 μM of BPA resulted in cytotoxic 
effects [9]. Moreover, the toxic effects of BPA at 100 μM (which equates our BPA 25 μg/ml 
dose) were observed as early as 24 hours [9]. Further, according to Lenie et al. [12], BPA 
exposure at 3 nM - 30 μM (doses that closely equate to our doses of BPA 0.001-10 μg/ml) did 
not affect early preantral follicle growth compared to control after 4 days of culture. Peretz et al. 
[10] reported that BPA at 100 μg/ml inhibited follicle growth as it did in our current study. 
Interestingly, BPA at 100 μg/ml inhibited follicle growth starting at 72 hours of culture in the 
Peretz et al. [10]
 
study, while it inhibited follicle growth beginning at 24 hours in the current 
study. This difference in the timing of BPA effects could be due to differences in strains of mice 
and animal ages in Peretz et al. [10] compared to our study. Peretz et al. [10] used FVB mice, 
whereas we used C57BL/6 mice. Additionally, Peretz et al. [10] used 32 day old mice, whereas 
we used 50-54 day old mice.  
Despite differences in the timing of inhibition of growth between our current study and 
the study by Peretz et al. [10], both studies showed that BPA treatment decreases estradiol levels.  
Estradiol is one of the main factors needed to stimulate follicle growth and to protect follicles 
from atresia [40].  Thus, decreased estradiol levels are another indication of impaired function of 
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the follicles that can be observed even when follicle growth is not inhibited. In the current study, 
after 96 hours of culture, BPA at 10-100 μg/ml significantly decreased estradiol levels in a dose 
dependent manner (Figure 5.2). Specifically, BPA at 10 μg/ml significantly decreased estradiol 
levels, even though it did not affect follicle growth compared to controls, whereas BPA at 25, 50 
and 100 μg/ml decreased both follicle growth and estradiol levels (Figures 5.1, 5.2). These 
findings are in agreement with the results by Peretz et al. [10], who reported that BPA at 10 and 
100 μg/ml significantly decreased estradiol levels compared to controls after 120 hours of 
culture. These data may suggest that exposure to BPA at 10, 25, 50 and 100 μg/ml pushes the 
follicles into cellular stress that results with impaired steroidogenesis followed by inhibition of 
growth with higher doses of BPA (25, 50 and 100 μg/ml). BPA at 10 μg/ml still allows the 
follicles to recover their growth, but not estradiol synthesis. 
Estradiol can protect follicles from atresia [40]
 
by suppressing the transcription of pro-
apoptotic factors such as Bax [41]. Previous studies also indicate that overexpression of the anti-
apoptotic factor Bcl2 enhances follicular growth and decreases apoptosis [42]. Studies also 
indicate that the balance between pro- and anti-apoptotic factors is a main determinant in 
whether the process of atresia will be initiated in follicles [43]. In our current study, Bcl2 levels 
(Figure 5.3) were significantly increased at BPA 10 and 25 μg/ml, whereas the pro-apoptotic 
factors Bax and Bad levels were not altered with any of the BPA treatments compared to controls 
(data not shown). Therefore, it is likely that BPA-induced changes in the ratio of pro- and anti-
apoptotic factors to favor an anti-apoptotic state may be an attempt of the follicles to restore 
normal growth following treatment with BPA 10 and 25 μg/ml. This attempt is not completely 
successful because follicles were only able to retain normal growth at BPA 10 μg/ml, but not at 
the higher tested doses. At higher doses, it may be that the follicular damage caused by BPA (25-
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100 μg/ml) was too profound to allow the follicles to be rescued or even partially protected by 
increasing expression of anti-apoptotic factors such as Bcl2. Xu et al. [9] have shown that BPA 
can induce apoptosis in isolated granulosa cells at concentration as low as 100 pM [9]. Therefore 
the difference in doses required to cause apoptosis in our study versus that by Xu et al. [9] can be 
due to the fact that we cultured whole follicles, whereas Xu et al. [9] cultured isolated granulosa 
cells. Interestingly, Peretz et al. [11] measured expression levels of Bax and Bcl2 in isolated 
antral follicles cultured with doses of BPA at 1, 10, and 100 μg/ml from 32-35 day old FVB 
mice. Their results indicate that at 96 hours, BPA at 100 μg/ml treatment significantly increased 
expression of both Bax and Bcl2. Again, this difference between the study by Peretz et al. [11] 
and the current study could be due to difference in the age and strain of mice that were used in 
both studies. 
The AHR signaling pathway plays a major role in regulating follicle growth and estradiol 
levels in the ovary and in mediating the toxic effects of other environmental chemicals (e.g., 
dioxins, polycyclic aromatic hydrocarbons) [21-23]. A few studies have examined the AHR as a 
potential mediator of the toxic effects of BPA [27, 28, 44-46]. However, only Nishizawa et al. 
[27]
 
have examined the AHR-BPA relationship in the gonads. The researchers observed elevated 
gonadal Ahr expression following in utero exposure to BPA.  Therefore, we investigated 
expression levels of major factors in the AHR signaling pathway following BPA exposure in our 
isolated follicle culture system. Interestingly, there were no striking differences in the expression 
of major factors in the AHR signaling pathway in WT follicles treated with BPA versus WT 
follicles treated with DMSO. These results are similar to what has been observed following 
treatment of cultured mouse antral follicles even with the potent ligand of the AHR TCDD,
 
in 
which the Ahr expression in TCDD treated follicles was not different than controls [47].  
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In the absence of the Ahr, however, antral follicles were rescued from BPA (25 μg/ml) 
induced inhibition of growth. This recovery occurs only at BPA 25 μg/ml and only starts at 72 
hours. Interestingly, the rescue of follicular growth was not observed at BPA 50 or 100 μg/ml. 
This may be because different doses of BPA may act through different signaling pathways to 
exert its toxic effects. It may also be that higher doses of BPA are cytotoxic to the follicles and 
that the follicles cannot be rescued from BPA exposure at higher doses even when removing the 
Ahr. These results are in agreement with other studies that have shown that disruption of the 
normal activity of the AHR reduces the toxic effects of other chemicals in the ovary. For 
example, α-napthoflavone, a known AHR inhibitor, reduces the toxic effects of benzo(a)pyrene, 
3-methylcholanthrene, and 7,12-dimethylbenz(a)anthracene on the ovary [48-50],
 
whereas 
TCDD, a potent AHR agonist, decreases tumorgenic cell proliferation [51]. Further, 
Basavarajappa et al. [47], who used a similar bioassay to the one that was used in our current 
study reported that AhrKO follicles treated with the pesticide methoxychlor at 10 μg/ml are also 
partially protected from inhibition of growth. These findings suggest that the AHR differentially 
modulates the toxic effects on follicular growth caused by BPA as well as other chemicals such 
as methoxychlor. 
Lastly, unlike the case with follicular growth, BPA treatment of AhrKO follicles resulted 
in similar estradiol levels to what we observed with WT follicles treated with BPA. These data 
are highly suggestive that the AHR signaling pathway is not a major route through which BPA 
exerts its toxic effects on the steroidogenic capacity of the follicles. These results add to a 
number of publications on the other potential targets through which BPA exerts its toxic effects 
on steroidogenesis. For example, Peretz et al. [10]
 
concluded that BPA treatment of antral 
follicles may interfere steroidogenesis by inhibiting with cholesterol uptake and metabolism by 
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decreasing the expression of the rate limiting factors steroidogenic acute regulatory protein 
(StAR) and cytochrome P450 cholesterol side chain cleavage (Cyp11a1).  Similar conclusions 
were also published by other researchers in other species [52]. Our results indicate that it is 
unlikely that any of these effects of BPA on steroidogenesis are mediated by the AHR. 
5.6 Conclusions 
Overall findings from the current study expand our knowledge regarding the toxic effects 
of a wide range of BPA doses in ovarian follicles. The examined range of doses represents both 
human exposure and environmentally relevant levels. Results from our study indicate that BPA 
in a linear dose-response manner decreases in vitro antral follicle growth and decreases synthesis 
of estradiol. BPA also alters expression levels of Bcl2, a factor that is involved in the process of 
follicular atresia. However, BPA treatment did not dramatically alter genes in the AHR signaling 
pathway. BPA-induced inhibition of follicle growth, however, was partially rescued in the 
absence of the Ahr, indicating that the AHR signaling pathway is partially involved in mediating 
the toxic effects of BPA on the growth of cultured mouse antral follicles. Further studies are 
needed to better understand the mechanism by which the AHR signaling pathway mediates the 
toxic effects of BPA (25 μg/ml). 
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5.8 Figures 
Figure 5.1: Effect of in vitro BPA exposure on wild-type mouse antral follicle growth. 
 
 
Antral follicles mechanically isolated from wild-type mice were individually cultured with 
vehicle control (DMSO) or BPA (0.001-100 μg/ml) for 96 hours. During the culture, follicle 
diameters were measured and then were converted to percent change from baseline (time 0). 
Graph represents means ± SEM from 3-4 separate experiments (at least five follicles per 
treatment). Asterisks represent significant differences from DMSO per time point; p≤0.05.  
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Figure 5.2: Effect of in vitro BPA exposure on estradiol synthesis by wild-type mouse antral 
follicles. 
 
 
 
 
 
 
Antral follicles mechanically isolated from wild-type mice were individually cultured with 
vehicle control (DMSO) or BPA (0.001-100 μg/ml). After 96 hours, the media were collected 
and analyzed for estradiol levels.  Graph represents means ± SEM from three separate 
experiments (at least three follicles per treatment, per experiment). Asterisks represent 
significant differences from DMSO; p≤0.05. 
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Figure 5.3: Effect of 96 hours in vitro BPA exposure on expression of Bcl2. 
 
 
 
 
 
Antral follicles isolated from wild-type mice were treated with vehicle control (DMSO) or BPA 
(0.001-100 μg/ml) and cultured for 96 hours. Expression levels of Bcl2 were measured using 
qPCR. Data represent means ± SEM from at least three separate experiments. Asterisks represent 
significant differences from DMSO; p≤0.05. 
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Figure 5.4: Effect of 24 hours in vitro BPA exposure on expression of Cyp1b1 (a), Arnt (b), Ahr (c), and Ahrr (d). 
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hours. Expression levels of Cyp1b1 (a), Arnt (b), Ahr (c), and Ahrr (d) were measured using qPCR. Data represent means ± SEM 
from at least three separate experiments. Asterisks represent significant differences from DMSO; p≤0.05. 
 
104 
 
Figure 5.5: Effect of 96 hours in vitro BPA exposure on expression of Cyp1b1 (a), Arnt (b), Ahr (c), and Ahrr (d).  
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Figure 5.6: Effect of in vitro BPA exposure on AhrKO mouse antral follicle growth. 
 
 
Antral follicles mechanically isolated from AhrKO mice were individually cultured with vehicle 
control (DMSO) or BPA (0.001-100 μg/ml) for 96 hours. During the culture, follicle diameters 
were measured and then were converted to percent change from baseline (time 0). Graph 
represents means ± SEM from 3-4 separate experiments (at least five follicles per treatment). 
Asterisks represent significant differences from DMSO per time point; p≤0.05.  
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Figure 5.7: Effect of in vitro BPA exposure on estradiol synthesis by AhrKO mouse antral 
follicles. 
 
 
 
 
Antral follicles mechanically isolated from AhrKO mice were individually cultured with vehicle 
control (DMSO) or BPA (1-100 μg/ml). After 96 hours, the media were collected and analyzed 
for estradiol levels.  Graph represents means ± SEM from three separate experiments (four 
follicles per treatment, per experiment). Asterisks represent significant differences from DMSO; 
p≤0.05. 
 
 
0
5
10
15
20
25
30
DMSO BPA 1 BPA 10 BPA 25 BPA 50 BPA 100
N
o
rm
al
iz
ed
 e
st
ra
d
io
l 
le
v
el
s 
 (
p
g
/m
l/
μ
m
) 
Treatment 
* 
* 
* 
* 
107 
 
5.9 References 
 [1] Cao XL, Perez-Locas C, Dufresne G, Clement G, Popovic S, Beraldin F et al. 
Concentrations of bisphenol A in the composite food samples from the 2008 Canadian 
total diet study in Quebec City and dietary intake estimates. Food Addit Contam Part A 
Chem Anal Control Expo Risk Assess 2011; 28:791-8. 
 [2]  Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y. Determination of bisphenol A 
concentrations in human biological fluids reveals significant early prenatal exposure. 
Hum Reprod 2002; 17:2839-41. 
 [3]  Craig ZR, Wang W, Flaws JA. Endocrine-disrupting chemicals in ovarian function: 
effects on steroidogenesis, metabolism and nuclear receptor signaling. Reproduction 
2011; 142:633-46. 
 [4]  Ehrlich S, Williams PL, Missmer SA, Flaws JA, Berry KF, Calafat AM et al. Urinary 
bisphenol A concentrations and implantation failure among women undergoing in vitro 
fertilization. Environ Health Perspect 2012; 120:978-83. 
 [5]  Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye X, Calafat AM et al. Urinary 
bisphenol A concentrations and early reproductive health outcomes among women 
undergoing IVF. Hum Reprod 2012; 27:3583-92. 
 [6]  Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between 
androgen and the endocrine disruptor, bisphenol A, in normal women and women with 
ovarian dysfunction. Endocr J 2004; 51:165-9. 
 [7]  Suzuki A, Sugihara A, Uchida K, Sato T, Ohta Y, Katsu Y et al. Developmental effects 
of perinatal exposure to bisphenol-A and diethylstilbestrol on reproductive organs in 
female mice. Reprod Toxicol 2002; 16:107-16. 
 [8]  Zhang W, Fang Y, Shi X, Zhang M, Wang X, Tan Y. Effect of bisphenol A on the 
EGFR-STAT3 pathway in MCF-7 breast cancer cells. Mol Med Rep 2012; 5:41-7. 
 [9]  Xu J, Osuga Y, Yano T, Morita Y, Tang X, Fujiwara T et al. Bisphenol A induces 
apoptosis and G2-to-M arrest of ovarian granulosa cells. Biochem Biophys Res Commun 
2002; 292:456-62. 
 [10]  Peretz J, Gupta RK, Singh J, Hernandez-Ochoa I, Flaws JA. Bisphenol A impairs follicle 
growth, inhibits steroidogenesis, and downregulates rate-limiting enzymes in the estradiol 
biosynthesis pathway. Toxicol Sci 2011; 119:209-17. 
 [11]  Peretz J, Craig ZR, Flaws JA. Bisphenol A inhibits follicle growth and induces atresia in 
cultured mouse antral follicles independently of the genomic estrogenic pathway. Biol 
Reprod 2012; 87:63. 
108 
 
 [12] Lenie S, Cortvrindt R, Eichenlaub-Ritter U, Smitz J. Continuous exposure to bisphenol A 
during in vitro follicular development induces meiotic abnormalities. Mutat Res 2008; 
651:71-81. 
 [13]  Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM. Bisphenol-A and 
the great divide: a review of controversies in the field of endocrine disruption. Endocr 
Rev 2009; 30:75-95. 
 [14]  Sengupta S, Obiorah I, Maximov P, Curpan R, Jordan V. Molecular mechanism of action 
of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and 
apoptosis of breast cancer cells. Br J Pharmacol 2013; 169:167-78. 
 [15]  Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, Ben Jonathan N. 
Bisphenol A at environmentally relevant doses inhibits adiponectin release from human 
adipose tissue explants and adipocytes. Environ Health Perspect 2008; 116:1642-7. 
 [16]  Vinas R, Watson CS. Bisphenol S disrupts estradiol-induced nongenomic signaling in a 
rat pituitary cell line: effects on cell functions. Environ Health Perspect 2013; 121:352-8. 
 [17]  Teng C, Goodwin B, Shockley K, Xia M, Huang R, Norris J et al. Bisphenol A affects 
androgen receptor function via multiple mechanisms. Chem Biol Interact 2013. 
 [18]  Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, Kanamoto N et al. Thyroid 
hormone action is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab 
2002; 87:5185-90. 
 [19]  Rubin BS. Bisphenol A: an endocrine disruptor with widespread exposure and multiple 
effects. J Steroid Biochem Mol Biol 2011; 127:27-34. 
 [20]  Poland A, Knutson JC. 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated 
aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol 
Toxicol 1982; 22:517-54. 
 [21]  Puga A, Ma C, Marlowe JL. The aryl hydrocarbon receptor cross-talks with multiple 
signal transduction pathways. Biochem Pharmacol 2009; 77:713-22. 
 [22]  Abel J, Haarmann-Stemmann T. An introduction to the molecular basics of aryl 
hydrocarbon receptor biology. Biol Chem 2010; 391:1235-48. 
 [23]  Pollenz RS. The mechanism of AH receptor protein down-regulation (degradation) and 
its impact on AH receptor-mediated gene regulation. Chem Biol Interact 2002; 141:41-
61. 
 [24]  Hernandez-Ochoa I, Karman BN, Flaws JA. The role of the aryl hydrocarbon receptor in 
the female reproductive system. Biochem Pharmacol 2009; 77:547-59. 
109 
 
 [25] Bussmann UA, Bussmann LE, Baranao JL. An aryl hydrocarbon receptor agonist 
amplifies the mitogenic actions of estradiol in granulosa cells: evidence of involvement 
of the cognate receptors. Biol Reprod 2006; 74:417-26. 
 [26]  Safe S, Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-
talk and mechanisms of action. Chem Res Toxicol 2003; 16:807-16. 
 [27]  Nishizawa H, Morita M, Sugimoto M, Imanishi S, Manabe N. Effects of in utero 
exposure to bisphenol A on mRNA expression of arylhydrocarbon and retinoid receptors 
in murine embryos. J Reprod Dev 2005; 51:315-24. 
 [28]  Bonefeld-Jorgensen EC, Long M, Hofmeister MV, Vinggaard AM. Endocrine-disrupting 
potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-
octylphenol in vitro: new data and a brief review. Environ Health Perspect 2007; 115 
Suppl 1:69-76. 
 [29]  Swedenborg E, Pongratz I. AhR and ARNT modulate ER signaling. Toxicology 2010; 
268:132-8. 
 [30]  Karman BN, Basavarajappa MS, Craig ZR, Flaws JA. 2,3,7,8-Tetrachlorodibenzo-p-
dioxin activates the aryl hydrocarbon receptor and alters sex steroid hormone secretion 
without affecting growth of mouse antral follicles in vitro. Toxicol Appl Pharmacol 2012; 
261:88-96. 
 [31]  Flint S, Markle T, Thompson S, Wallace E. Bisphenol A exposure, effects, and policy: a 
wildlife perspective. J Environ Manage 2012; 104:19-34. 
 [32]  Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgartten FJ, Schoenfelder 
G. Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to 
bisphenol A. Cien Saude Colet 2012; 17:407-34. 
 [33]  Schmidt JV, Su GH, Reddy JK, Simon MC, Bradfield CA. Characterization of a murine 
Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc 
Natl Acad Sci U S A 1996; 93:6731-6. 
 [34]  Benedict JC, Lin TM, Loeffler IK, Peterson RE, Flaws JA. Physiological role of the aryl 
hydrocarbon receptor in mouse ovary development. Toxicol Sci 2000; 56:382-8. 
 [35]  Hernandez-Ochoa I, Barnett-Ringgold KR, Dehlinger SL, Gupta RK, Leslie TC, Roby 
KF et al. The ability of the aryl hydrocarbon receptor to regulate ovarian follicle growth 
and estradiol biosynthesis in mice depends on stage of sexual maturity. Biol Reprod 
2010; 83:698-706. 
 [36]  Miller KP, Gupta RK, Greenfeld CR, Babus JK, Flaws JA. Methoxychlor directly affects 
ovarian antral follicle growth and atresia through Bcl-2- and Bax-mediated pathways. 
Toxicol Sci 2005; 88:213-21. 
110 
 
 [37]  Abbott BD, Schmid JE, Brown JG, Wood CR, White RD, Buckalew AR et al. RT-PCR 
quantification of AHR, ARNT, GR, and CYP1A1 mRNA in craniofacial tissues of 
embryonic mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and hydrocortisone. 
Toxicol Sci 1999; 47:76-85. 
 [38]  Craig ZR, Hannon PR, Wang W, Ziv-Gal A, Flaws JA. Di-n-butyl phthalate disrupts the 
expression of genes involved in cell cycle and apoptotic pathways in mouse ovarian 
antral follicles. Biol Reprod 2013; 88:23. 
 [39]  Wozniak AL, Bulayeva NN, Watson CS. Xenoestrogens at picomolar to nanomolar 
concentrations trigger membrane estrogen receptor-alpha-mediated Ca2+ fluxes and 
prolactin release in GH3/B6 pituitary tumor cells. Environ Health Perspect 2005; 
113:431-9. 
 [40]  Quirk SM, Cowan RG, Harman RM, Hu CL, Porter DA. Ovarian follicular growth and 
atresia: the relationship between cell proliferation and survival. J Anim Sci 2004; 82 E-
Suppl:E40-E52. 
 [41]  Matsuda F, Inoue N, Manabe N, Ohkura S. Follicular growth and atresia in mammalian 
ovaries: regulation by survival and death of granulosa cells. J Reprod Dev 2012; 58:44-
50. 
 [42]  Hsu SY, Lai RJ, Finegold M, Hsueh AJ. Targeted overexpression of Bcl-2 in ovaries of 
transgenic mice leads to decreased follicle apoptosis, enhanced folliculogenesis, and 
increased germ cell tumorigenesis. Endocrinology 1996; 137:4837-43. 
 [43]  Riou C, Tonoli H, Bernier-Valentin F, Rabilloud R, Fonlupt P, Rousset B. Susceptibility 
of differentiated thyrocytes in primary culture to undergo apoptosis after exposure to 
hydrogen peroxide: relation with the level of expression of apoptosis regulatory proteins, 
Bcl-2 and Bax. Endocrinology 1999; 140:1990-7. 
 [44]  Nishizawa H, Imanishi S, Manabe N. Effects of exposure in utero to bisphenol a on the 
expression of aryl hydrocarbon receptor, related factors, and xenobiotic metabolizing 
enzymes in murine embryos. J Reprod Dev 2005; 51:593-605. 
 [45]  Kruger T, Long M, Bonefeld-Jorgensen EC. Plastic components affect the activation of 
the aryl hydrocarbon and the androgen receptor. Toxicology 2008; 246:112-23. 
 [46]  Imanishi S, Manabe N, Nishizawa H, Morita M, Sugimoto M, Iwahori M et al. Effects of 
oral exposure of bisphenol A on mRNA expression of nuclear receptors in murine 
placentae assessed by DNA microarray. J Reprod Dev 2003; 49:329-36. 
 [47]  Basavarajappa MS, Hernandez-Ochoa I, Wang W, Flaws JA. Methoxychlor inhibits 
growth and induces atresia through the aryl hydrocarbon receptor pathway in mouse 
ovarian antral follicles. Reprod Toxicol 2012; 34:16-21. 
 [48]  Cooper AR, Moley KH. Maternal tobacco use and its preimplantation effects on fertility: 
more reasons to stop smoking. Semin Reprod Med 2008; 26:204-12. 
111 
 
 [49]  Shiromizu K, Mattison DR. Murine oocyte destruction following intraovarian treatment 
with 3-methylcholanthrene or 7,12-dimethylbenz(a)anthracene: protection by alpha-
naphthoflavone. Teratog Carcinog Mutagen 1985; 5:463-72. 
 [50]  Shiromizu K, Mattison DR. The effect of intraovarian injection of benzo(a)pyrene on 
primordial oocyte number and ovarian aryl hydrocarbon [benzo(a)pyrene] hydroxylase 
activity. Toxicol Appl Pharmacol 1984; 76:18-25. 
 [51]  Holcomb M, Safe S. Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary 
tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett 1994; 82:43-7. 
 [52]  Mlynarcikova A, Kolena J, Fickova M, Scsukova S. Alterations in steroid hormone 
production by porcine ovarian granulosa cells caused by bisphenol A and bisphenol A 
dimethacrylate. Mol Cell Endocrinol 2005; 244:57-62. 
 
 
  
112 
 
CHAPTER VI 
Summary and future directions 
6.1 Summary and future directions 
The main goal of my doctoral work was to understand whether major factors in the AHR 
signaling pathway are involved in adverse reproductive outcomes. I focused on potential risk 
factors of menopausal hot flashes and sleep disturbances. These symptoms can severely affect 
the daily activity of women who experience them. Unfortunately, it is difficult to treat them 
because their etiology is unknown. I also focused on the ability of BPA to alter steroidogenesis 
and inhibit ovarian follicular growth. The selected outcomes were used as indicators of ovarian 
toxicity that may eventually lead to impaired fertility.  
Specifically, in Chapter III, I wanted to determine if selected single nucleotide 
polymorphisms in the AHR signaling pathway were associated with the risk of menopausal hot 
flashes via pathways that involve changes in serum E2 concentration.  I was able to show that 
only the downstream target gene CYP1B1 was associated with long-lasting menopausal hot 
flashes via pathways that may involve changes in serum E2 concentrations. Additionally, 
association analysis of the combined CYP1B1 SNPs showed a significant association with hot 
flash severity. However, the other selected SNPs in the AHR signaling pathway were not 
associated with the risk of hot flashes. In Chapter IV, I wanted to determine if selected SNPs in 
the AHR signaling pathway and CLOCK were associated with the risk of menopausal sleep 
disturbances (i.e., insomnia and early awakening). I was able to show that only the selected SNPs 
in the AHRR and CLOCK may play a role in decreasing the risk of experiencing insomnia during 
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the menopausal transition. The selected SNPs or combinations of SNPs were not associated with 
early awakening. 
Both chapters III and IV dealt with two of the main reasons women seek medical 
assistance during the menopausal transition. Though some associations were found with the 
examined SNPs and these symptoms, other avenues of research are still needed. Additional areas 
to further examine are the effects of the SNPs on expression levels of factors in the AHR 
signaling pathway. For example, Helmig et al. [1]
 
examined the effects of the SNP in the AHR 
(rs2066853; Arg>Lys) on the expression levels of major factors in the AHR signaling pathway. 
The study results indicate that participants carrying the variant allele (AHR_Lys/Lys or 
AHR_Arg/Lys) had significantly lower mRNA levels of AHR, ARNT, and CYP1B1 compared to 
participants who did not carry the variant allele (i.e., AHR_Arg/Arg). These results can further 
interpreted as a lower potential of clearance of ligands by the AHR signaling pathway.  
Moreover, it will be interesting to examine the associations between levels of various 
EDCs and adverse reproductive outcomes such as those that were examined in my studies (i.e., 
menopausal symptoms). Various EDCs have already been linked with adverse reproductive 
outcomes such as anovulation, infertility, and premature ovarian failure [2]. However, no studies 
have tested the association between EDCs and symptoms during the menopausal transition. 
Future studies can combine data of analyses similar to what was conducted by Helming et al. [1], 
with measurements of levels of various EDCs. The final results can then be used for association 
studies that will compare symptomatic women to asymptomatic women.  
In Chapter V, I wanted to determine if BPA acts through the AHR signaling pathway to 
increase E2 metabolism, leading to low E2 levels, followed by slow follicular growth. I was able 
to examine a wide range of doses of BPA, including a dose that encompasses the levels that were 
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measured in follicular fluid of women undergoing IVF treatments [3]. I showed that BPA 
significantly inhibits follicle growth at doses (BPA 25 and 50 μg/ml) that are lower  than what 
was previously published by Peretz et al. [4] (BPA 100 μg/ml) and that BPA selectively 
decreases E2 levels synthesized by cultured antral follicles even at a dose that follicular growth 
was not inhibited (BPA 10 μg/ml). However, BPA exposure can affect other follicular endpoints 
such as oocyte quality, and ovulation capabilities. In support of this possibility are the findings 
by Ehrlich et al. [5, 6] who reported inverse relationship between urinary BPA levels and IVF 
success indicators (e.g., blastocyst formation, number of normally fertilizing oocytes, number of 
oocyte retrieved, and implantation failure). Future studies can give a better understanding of 
whether other functions of the follicle are altered following treatment with BPA. 
My results also suggest that deletion of the Ahr partially rescues the follicles from 
inhibition of growth, but not from decreased E2 synthesis. My findings strongly suggest that the 
AHR only partially mediates the toxic effects of BPA at the examined doses. Future studies that 
will focus on a narrower dose range (i.e., 1-30 μg/ml) may give us a better understanding of the 
mechanism of BPA toxicity in ovarian follicles. These studies can further examine the role of the 
AHR in mediating the toxic effects of BPA as well as exploring other signaling pathways. 
Specifically, future studies can focus on the insulin signaling and glucose homeostasis that are 
important for proper reproductive function [7, 8]. Interestingly, in humans, BPA exposure was 
linked to insulin resistance and is considered to be diabetogenic agent [9, 10]. Additionally, 
several researchers have used various animal models and cell types to examine the role of the 
insulin signaling pathway in mediating the toxic effects of BPA [9, 11, 12]. For example, D’cruz 
et al. [12]
 
showed that BPA can interact with glucose transporters (GLUT 2 and GLUT8; in 
silico) and that it inhibits glucose uptake and steroidogenesis in rats testes.  
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Lastly, in my studies, I focused only on BPA. Since our environment is enriched with 
other chemicals, it is possible that BPA will have greater toxic effects (additive) when introduced 
to ovarian follicles with other compounds such as phthalates. In support of this possibility are 
findings by Kruger et al. [13]
 
who showed that a mixture of BPA with other compounds like 
alkylphenols and phthalates has a greater AHR agonistic effect then the individual compounds in 
an AHR-CALUX assay.  
Overall, results from my studies expand the knowledge about novel risk factors of 
menopausal symptoms, and potential mechanism of action related to the toxic effects of BPA on 
ovarian follicles. Findings from my studies can further assist in diagnosing populations at a 
higher risk of adverse reproductive outcomes and perhaps, lead to development of targeted 
therapeutic agents in the future.  
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